Shannon N. Westin, M.D., M.P.H., F.A.S.C.O., F.A.C.O.G.

Peer-Reviewed Articles

1. Piha-Paul, SA, Tseng, C, Thompson, E, Stafford, RJ, Le, H, Kang, L, Fu, S, Tsimberidou, AM, Blumenschein, GR, Rodon Ahnert, J, Slopis, JM, Hong, DS, Naing, A, Meric-Bernstam, F, Ng, CS, Westin, SN, Sood, AK. Phase I study of bevacizumab and temsirolimus combination therapy in advanced malignancies. Oncologist 31(3), 2026. e-Pub 2026. PMID: 41389341.
2. Westin, SN, Moore, KM, Chon, HS, Pepin, JT, Salinas, EA, Starks, D, DiSilvestro, P, Slomovitz, BM, Vettus, E, Gálvez-Montosa, F, Agyemang-Prempeh, K, Zagouri, F, Jae, WK, Gao, Q, Mejia, FC, De Melo, AC, Nishikawa, T, Kowgier, M, Iyer, S, Wang, Y, Van Nieuwenhuysen, E. Biomarker heterogeneity and efficacy of durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib in patients with mismatch repair proficient endometrial cancer. Gynecologic oncology 206:54-64, 2026. e-Pub 2026. PMID: 41690202.
3. Ma, X, Hsu, YC, Asare, A, Zhang, K, Glassman, D, Handley, KF, Foster, KI, Sharma, K, Westin, SN, Jazaeri, AA, Fleming, N, Bhattacharya, PK, Jiang, X, Sood, AK, Shams, S. A pioneering artificial intelligence tool to predict treatment outcomes in ovarian cancer via diagnostic laparoscopy. Scientific reports 15(1), 2025. e-Pub 2025. PMID: 40281006.
4. Wilke, RN, Liu, J, Westin, SN, Fellman, B, Sims, TT, Pham, MM, Rangel, KM, Sey, E, Rauh-Hain, JA, Lu, KH, Sood, AK, Fleming, N. The association of the chemotherapy response score and homologous recombination deficiency in patients undergoing interval tumor reductive surgery following neoadjuvant chemotherapy. International Journal of Gynecological Cancer 35(11), 2025. e-Pub 2025. PMID: 39414313.
5. Knisely, A, Dai, Y, Barlow, GL, Lee, S, Lawson, BC, Clark, HD, Fellman, B, Yuan, Y, Lu, W, Lubo Julio, IC, Lazcano, RN, Chelvanambi, M, Melendez, B, Singh, BB, Singh, B, Wani, K, Chen, J, Yeh, CC, Gao, J, Barnes, S, Shi, O, Khan, KB, Serrano, A, Gomez Bolanos, L, Scalise, CB, Cheung, SK, Dutta, P, Velichko, S, ElNaggar, AC, Liu, MC, Wilke, RN, How, JA, Ramondetta, LM, Boruta II, DM, Richardson, G, Shafer, A, Westin, SN, Sims, TT, Sood, AK, Ramirez, PT, Lazar, A, Soliman, PT, Lu, KH, Haymaker, CL, Solis Soto, LM, Wargo, J, Grisham, RN, Wucherpfennig, K, Wang, L, Jazaeri, AA. Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy. Clinical Cancer Research 31(19):4122-4135, 2025. e-Pub 2025. PMID: 40748258.
6. Brodsky, AL, Sun, CC, Cobb, LP, Westin, SN, Malpica, A, Gershenson, DM. Ovarian mixed low- and high-grade serous carcinoma as a synchronous or metachronous phenomenon. Gynecologic oncology 200:130-136, 2025. e-Pub 2025. PMID: 40749518.
7. Dai, Y, Knisely, A, Yano, M, Dang, M, Hinchcliff, EM, Lee, S, Welp, A, Chelvanambi, M, Lastrapes, M, Liu, H, Yuan, Z, Wang, C, Nie, H, Jean, S, Montaner, LJ, Hou, J, Patel, A, Patel, S, Fellman, B, Yuan, Y, Sun, B, Pandurengan, RK, Cuentas, EP, Celestino, J, Liu, Y, Liu, J, Hillman, RT, Westin, SN, Sood, AK, Soliman, PT, Shafer, A, Meyer, LA, Gershenson, DM, Vining, D, Ganeshan, DM, Lu, KH, Wargo, J, Peng, W, Zhang, R, Wang, L, Jazaeri, AA. PPP2R1A mutations portend improved survival after cancer immunotherapy. Nature 644(8076):537-546, 2025. e-Pub 2025. PMID: 40604275.
8. Asare, A, Previs, RA, Spinosa, D, Fellman, B, Scott, AL, Mulder, I, Mahmoud, M, Enbaya, A, Siedel, J, Cobb, LP, Soliman, PT, Sood, AK, Coleman, R, Secord, AA, Westin, SN. Bevacizumab beyond progression. Gynecologic oncology 194:112-118, 2025. e-Pub 2025. PMID: 39987772.
9. Corvigno, S, Yao, J, Asare, A, Zhao, L, Celestino, J, Hajek, RA, Goette, EA, Rogers, RT, Montoya, RN, Song, P, Zhang, Q, Song, X, Mohammad, MM, Shaw, KR, Zhang, J, Lu, KH, Jazaeri, AA, Westin, SN, Sood, AK, Lee, S. Longitudinal genomic profiling of chemotherapy-related CHIP variants in patients with ovarian cancer. Frontiers in Oncology 15, 2025. e-Pub 2025. PMID: 40365343.
10. Awasthi, S, Dobrolecki, LE, Sallas, C, Zhang, X, Li, Y, Khazaei, S, Ghosh, S, Jeter, CR, Liu, J, Mills, GB, Westin, SN, Lewis, MT, Peng, W, Sood, AK, Yap, TA, Yi, SS, McGrail, DJ, Sahni, N. UBA1 inhibition sensitizes cancer cells to PARP inhibitors. Cell Reports Medicine 5(12), 2024. e-Pub 2024. PMID: 39626673.
11. Brown, J, Miller, A, Holman, LL, Backes, F, Nagel, C, Bender, D, Miller, DS, Powell, MA, Westin, SN, Bonebrake, AJ, Muller, CY, Secord, AA, Crane, EK, Schorge, JO, Tew, WP, Sood, AK, Bookman, M, Aghajanian, C, Gershenson, DM. Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors. Gynecologic oncology 190:283-290, 2024. e-Pub 2024. PMID: 39265466.
12. How JA, Dang M, Lee S, Fellman B, Westin SN, Sood AK, Fleming ND, Shafer A, Yuan Y, Liu J, Zhao L, Celestino J, Hajek R, Morgan MB, Parra ER, Laberiano Fernandez CD, Arrechedera CA, Solis Soto LM, Schmeler KM, Nick A, Lu KH, Coleman R, Wang L, Jazaeri AA. Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial. Med 6(1), 2024. e-Pub 2024. PMID: 39151421.
13. Hutchcraft ML, Rios-Doria E, Sia TY, Teplinsky E, Westin SN, Nelson G. #HashtagThis - Everything you need to know about launching your gynecologic oncology social media research career: A report from Gynecologic Oncology Reports and Society of Gynecologic Oncology Education Committee. Gynecol Oncol Rep 54:101451, 2024. e-Pub 2024. PMID: 39045261.
14. Son J, Zhang Y, Lin H, Mirallas O, Alvarez Ballesteros P, Nardo M, Clark N, Hillman RT, Campbell E, Holla V, Johnson AM, Biter AB, Yuan Y, Cobb LP, Gershenson DM, Jazaeri AA, Lu KH, Soliman PT, Westin SN, Euscher ED, Lawson BC, Yang RK, Meric-Bernstam F, Hong DS. Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers. Clin Cancer Res 30(14):2986-2995, 2024. e-Pub 2024. PMID: 38687597.
15. Wagner P, Levine EA, Kim AC, Shen P, Fleming ND, Westin SN, Berry LK, Karakousis GC, Tanyi JL, Olson MT, Madajewski B, Ostrander B, Krishnan K, Balch CM, Bartlett DL. Detection of Residual Peritoneal Metastases Following Cytoreductive Surgery Using Pegsitacianine, a pH-Sensitive Imaging Agent: Final Results from a Phase II Study. Ann Surg Oncol 31(7):4726-4734, 2024. e-Pub 2024. PMID: 38622456.
16. Wagner P, Levine EA, Kim AC, Shen P, Fleming ND, Westin SN, Berry LK, Karakousis GC, Tanyi JL, Olson MT, Madajewski B, Ostrander B, Krishnan K, Balch CM, Bartlett DL. ASO Visual Abstract: Detection of Residual Peritoneal Metastases Following Cytoreductive Surgery Using Pegsitacianine, a pH-Sensitive Imaging Agent-Final Results from a Phase 2 Study. Ann Surg Oncol 31(7):4743-4744, 2024. e-Pub 2024. PMID: 38722420.
17. Bowen MB, Melendez B, Zhang Q, Yang RK, Fellman BM, Lawson BC, Adjei NN, Celestino J, Wani KM, Singh B, Urbauer DL, Lazar AJ, Lu KH, Wargo JA, Westin SN, Yates MS. Long-term follow-up of levonorgestrel intrauterine device for atypical hyperplasia and early endometrial cancer reveals relapse characterized by immune exhaustion. Clin Cancer Res 30(22):5073-5082, 2024. e-Pub 2024. PMID: 38922360.
18. Lawson BC, Marques-Piubelli ML, Westin SN, Malpica A. Folate Receptor Immunohistochemical Staining and Gynecologic Tumors: Initial Experience With 216 Cases. Int J Gynecol Pathol 44(2):167-173, 2024. e-Pub 2024. PMID: 38914019.
19. Knisely A, Hinchcliff EM, Gardiner E, Rangwala R, Lito K, Fellman B, Yuan Y, Sood AK, Westin SN, Lu KH, Jazaeri AA. Phase 1b study of batiraxcept in combination with durvalumab in patients with platinum-resistant ovarian cancer. iScience 27(5):109801, 2024. e-Pub 2024. PMID: 38726365.
20. How JA, Legarreta AF, Handley KF, Fellman B, Foster KI, Glassman D, Vuttaradhi VK, Brodsky AL, Lawson B, Frumovitz M, Westin SN, Ramondetta LM, Gershenson DM, Sood AK, Hillman RT. Serial cytoreductive surgery and survival outcomes in recurrent adult-type ovarian granulosa cell tumors. Am J Obstet Gynecol 230(5):544.e1-544.e13, 2024. e-Pub 2024. PMID: 38191019.
21. Knisely A, Hinchcliff E, Fellman B, Mosley A, Lito K, Hull S, Westin SN, Sood AK, Schmeler KM, Taylor JS, Huang SY, Sheth RA, Lu KH, Jazaeri AA. Phase 1b study of intraperitoneal ipilimumab and nivolumab in patients with recurrent gynecologic malignancies with peritoneal carcinomatosis. Med 5(4):311-320.e3, 2024. e-Pub 2024. PMID: 38471508.
22. Hinchcliff EM, Knisely A, Adjei N, Fellman B, Yuan Y, Patel A, Xu C, Westin SN, Sood AK, Soliman PT, Shafer A, Fleming ND, Gershenson DM, Vikram R, Bathala T, Vining D, Ganeshan DM, Lu KH, Sun CC, Meyer LA, Jazaeri AA. Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer. Cancer 130(7):1061-1071, 2024. e-Pub 2024. PMID: 38009662.
23. Flores Legarreta A, Saab R, Gonzales NR, Chisholm GB, Westin SN, Hillman RT, Frumovitz M. Neuroendocrine neoplasms of the ovary: a review of 63 cases. Int J Gynecol Cancer 34(4):566-573, 2024. e-Pub 2024. PMID: 38290783.
24. Westin SN, Moore K, Chon HS, Lee JY, Thomes Pepin J, Sundborg M, Shai A, de la Garza J, Nishio S, Gold MA, Wang K, McIntyre K, Tillmanns TD, Blank SV, Liu JH, McCollum M, Contreras Mejia F, Nishikawa T, Pennington K, Novak Z, De Melo AC, Sehouli J, Klasa-Mazurkiewicz D, Papadimitriou C, Gil-Martin M, Brasiuniene B, Donnelly C, Del Rosario PM, Liu X, Van Nieuwenhuysen E. Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial. J Clin Oncol 42(3):283-299, 2024. e-Pub 2024. PMID: 37864337.
25. Joseph R, Dasari SK, Umamaheswaran S, Mangala LS, Bayraktar E, Rodriguez-Aguayo C, Wu Y, Nguyen N, Powell RT, Sobieski M, Liu Y, Kim MS, Corvigno S, Foster K, Hanjra P, Vu TC, Chowdhury MA, Amero P, Stephan C, Lopez-Berestein G, Westin SN, Sood AK. EphA2- and HDAC-Targeted Combination Therapy in Endometrial Cancer. Int J Mol Sci 25(2), 2024. e-Pub 2024. PMID: 38279277.
26. Eyada, M, Michael, V, Fellman, B, Patel, S, Soliman, PT, How, JA, Jazaeri, AA, Fleming, N, Sood, AK, Westin, SN, Sims, TT. Oral cyclophosphamide plus bevacizumab in recurrent ovarian, fallopian tube and primary peritoneal cancer. Journal of Clinical Oncology 42(16), 2024. e-Pub 2024.
27. Eyada, M, Fellman, B, Patel, S, Michael, V, Soliman, PT, Sims, TT, How, JA, Jazaeri, AA, Fleming, N, Ramondetta, LM, Westin, SN. Gemcitabine plus cisplatin in recurrent ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology 42(16), 2024. e-Pub 2024.
28. Van Nieuwenhuysen, E, Baurain, JF, Chon, HS, Pepin, JT, Sundborg, M, Gold, MA, Kim, BG, Blank, S, Liu, J, McCollum, M, Mori, M, Jonuškienė, G, Moore, KM, Novak, Z, Ramos, P, de Padua, CJ, Gil-Martin, M, Kowgier, M, del Rosario, PM, Westin, SN. Durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer (EC) in DUO-E. Journal of Clinical Oncology 42(16_suppl):5595, 2024. e-Pub 2024.
29. Pepin, JT, Chon, HS, Sundborg, M, Gold, MA, Kim, BG, Blank, S, Liu, J, McCollum, M, Mori, M, Moore, KM, Diaz, JR, de Padua, CJ, Martinez-Garcia, J, Papadimitriou, C, An, KG, Póka, R, Kowgier, M, Oscroft, E, Van Nieuwenhuysen, E, Westin, SN. Safety and tolerability of durvalumab + carboplatin/paclitaxel followed by durvalumab 6 olaparib in patients with newly diagnosed advanced or recurrent endometrial cancer (EC) in the DUO-E/GOG-3041/ENGOT-EN10 trial. Journal of Clinical Oncology 42(16), 2024. e-Pub 2024.
30. Li Y, Dobrolecki LE, Sallas C, Zhang X, Kerr TD, Bisht D, Wang Y, Awasthi S, Kaundal B, Wu S, Peng W, Mendillo ML, Lu Y, Jeter CR, Peng G, Liu J, Westin SN, Sood AK, Lewis MT, Das J, Yi SS, Bedford MT, McGrail DJ, Sahni N. PRMT blockade induces defective DNA replication stress response and synergizes with PARP inhibition. Cell Rep Med 4(12):101326, 2023. e-Pub 2023. PMID: 38118413.
31. Jazaeri AA, Grisham R, Knisely A, Spranger S, Zamarin D, Hillman RT, Lawson BC, Burns KH, Lee S, Westin SN, Moiso E, Williams MJ, Bardhan NM, Pisanic T, Matulonis U, Weigelt B, Shih I, Konstantinopoulos PA, Gaillard S, Wang L, Aghajanian C, D'Andrea AD, Hammond P, Shah S, Wucherpfennig KW, Lu KH. Transforming ovarian cancer care by targeting minimal residual disease. Med 4(11):755-760, 2023. e-Pub 2023. PMID: 37951209.
32. Hong H, Glassman D, Westin SN. Ischemic bowel associated with newly diagnosed patent foramen ovale. Int J Gynecol Cancer 33(11):1833-1834, 2023. e-Pub 2023. PMID: 37666526.
33. Nasioudis D, Fernandez ML, Wong N, Powell DJ, Mills GB, Westin S, Fader AN, Carey MS, Simpkins F. The spectrum of MAPK-ERK pathway genomic alterations in gynecologic malignancies: Opportunities for novel therapeutic approaches. Gynecol Oncol 177:86-94, 2023. e-Pub 2023. PMID: 37657193.
34. Grisham RN, Slomovitz BM, Andrews N, Banerjee S, Brown J, Carey MS, Chui H, Coleman RL, Fader AN, Gaillard S, Gourley C, Sood AK, Monk BJ, Moore KN, Ray-Coquard I, Shih IM, Westin SN, Wong KK, Gershenson DM. Low-grade serous ovarian cancer: expert consensus report on the state of the science. Int J Gynecol Cancer 33(9):1331-1344, 2023. e-Pub 2023. PMID: 37591609.
35. Konski A, Deshmukh S, Klopp AH, Yeung AR, Westin SN, Thompson JS, Doncals DE, Cantuaria GHC, D'Souza DP, Chang A, Kundapur V, Mohan DS, Haas ML, Kim YB, Ferguson CL, Pugh SL, Kachnic LA, Bruner DW. Quality-adjusted survival in women with gynecologic malignancies receiving IMRT after surgery: A Ppatient Rreported Ooutcome study of NRG oncology's RTOG 1203. Gynecol Oncol 175:176-181, 2023. e-Pub 2023. PMID: 37393743.
36. Zhang X, Yao J, Li X, Niu N, Liu Y, Hajek RA, Peng G, Westin S, Sood AK, Liu J. Targeting polyploid giant cancer cells potentiates a therapeutic response and overcomes resistance to PARP inhibitors in ovarian cancer. Sci Adv 9(29):eadf7195, 2023. e-Pub 2023. PMID: 37478190.
37. Morris VK, Jazaeri A, Westin SN, Pettaway C, George S, Huey RW, Grinsfelder M, Shafer A, Johnson B, Vining D, Guo M, Fellman B, Frumovitz M. Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent/Metastatic Human Papillomavirus-Associated Cancers. Oncologist 28(7):618-623, 2023. e-Pub 2023. PMID: 37104874.
38. Foster KI, Shaw KRM, Jin J, Westin SN, Yap TA, Glassman DM, Jazaeri AA, Rauh-Hain JA, Lee S, Fellman BM, Ju Z, Liu Y, Fleming ND, Sood AK. Clinical implications of tumor-based next-generation sequencing in high-grade epithelial ovarian cancer. Cancer 129(11):1672-1680, 2023. e-Pub 2023. PMID: 36930815.
39. Foster KI, Flores Legarreta A, Kamat R, Handley KF, Glassman D, How JA, Lawson BC, Westin SN, Ramondetta LM, Frumovitz M, Gershenson DM, Sood AK, Hillman RT. Clinical outcomes of leuprolide acetate in the treatment of recurrent ovarian granulosa cell tumors. Am J Obstet Gynecol 228(6):724.e1-724.e9, 2023. e-Pub 2023. PMID: 36907533.
40. Fu S, Yao S, Yuan Y, Previs RA, Elias AD, Carvajal RD, George TJ, Yuan Y, Yu L, Westin SN, Xing Y, Dumbrava EE, Karp DD, Piha-Paul SA, Tsimberidou AM, Ahnert JR, Takebe N, Lu K, Keyomarsi K, Meric-Bernstam F. Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification. J Clin Oncol 41(9):1725-1734, 2023. e-Pub 2023. PMID: 36469840.
41. Glassman D, Kim MS, Spradlin M, Badal S, Taki M, Bhattacharya P, Dutta P, Kingsley CV, Foster KI, Animasahun O, Jeon JH, Achreja A, Jayaraman A, Kumar P, Nenwani M, Wuchu F, Bayraktar E, Wu Y, Stur E, Mangala L, Lee S, Yap TA, Westin SN, Eberlin LS, Nagrath D, Sood AK. Exploiting metabolic vulnerabilities after anti-VEGF antibody therapy in ovarian cancer. iScience 26(2):106020, 2023. e-Pub 2023. PMID: 36824283.
42. Dasari SK, Joseph R, Umamaheswaran S, Mangala LS, Bayraktar E, Rodriguez-Aguayo C, Wu Y, Nguyen N, Powell RT, Sobieski M, Liu Y, Chowdhury MA, Amero P, Stephan C, Lopez-Berestein G, Westin SN, Sood AK. Combination of EphA2- and Wee1-Targeted Therapies in Endometrial Cancer. Int J Mol Sci 24(4), 2023. e-Pub 2023. PMID: 36835335.
43. Son J, Lin HY, Fu S, Biter AB, Dumbrava EE, Karp DD, Naing A, Pant S, Piha-Paul SA, Rodon J, Subbiah V, Tsimberidou AM, Yap TA, Frumovitz MM, Jazaeri AA, Ramirez PT, Westin SN, Yuan Y, Meric-Bernstam F, Hong DS. Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer. J Immunother Precis Oncol 6(1):10-18, 2023. e-Pub 2023. PMID: 36751659.
44. Westin, SN. Managed Care Perspectives on the Treatment and Management of Ovarian Cancer. Journal of Managed Care Medicine 26(2):54-57, 2023. e-Pub 2023.
45. Westin SN, Fu S, Tsimberidou A, Piha-Paul S, Akhmedzhanov F, Yilmaz B, McQuinn L, Brink AL, Gong J, Leung CH, Lin H, Hong DS, Pant S, Carter B, Jazaeri A, Gershenson D, Sood AK, Coleman RL, Shah J, Meric-Bernstam F, Naing A. Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer. Gynecol Oncol 168:76-82, 2023. e-Pub 2023. PMID: 36423446.
46. Pham MM, Avila M, Hinchcliff E, Westin SN. Clinical Application of Poly(ADP-Ribose) Polymerase (PARP) Inhibitors in Ovarian Cancer. Cancer Treat Res 186:71-89, 2023. e-Pub 2023. PMID: 37978131.
47. Monk BJ, Parkinson C, Lim MC, O'Malley DM, Oaknin A, Wilson MK, Coleman RL, Lorusso D, Bessette P, Ghamande S, Christopoulou A, Provencher D, Prendergast E, Demirkiran F, Mikheeva O, Yeku O, Chudecka-Glaz A, Schenker M, Littell RD, Safra T, Chou HH, Morgan MA, Drochytek V, Barlin JN, Van Gorp T, Ueland F, Lindahl G, Anderson C, Collins DC, Moore K, Marme F, Westin SN, McNeish IA, Shih D, Lin KK, Goble S, Hume S, Fujiwara K, Kristeleit RS. A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). J Clin Oncol 40(34):3952-3964, 2022. e-Pub 2022. PMID: 35658487.
48. Kurnit KC, Nobre SP, Fellman BM, Iglesias DA, Lindemann K, Jhingran A, Eriksson AGZ, Ataseven B, Glaser GE, Mueller JJ, Westin SN, Soliman PT. Adjuvant therapy in women with early stage uterine serous carcinoma: A multi-institutional study. Gynecol Oncol 167(3):452-457, 2022. e-Pub 2022. PMID: 36243601.
49. Gershenson DM, Cobb LP, Westin SN, Zhang Y, Jazaeri A, Malpica A, Sun CC. Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survival. Gynecol Oncol 167(2):139-145, 2022. e-Pub 2022. PMID: 36137845.
50. Handley KF, Sims TT, Bateman NW, Glassman D, Foster KI, Lee S, Yao J, Yao H, Fellman BM, Liu J, Lu Z, Conrads KA, Hood BL, Barakat W, Zhao L, Zhang J, Westin SN, Celestino J, Rangel KM, Badal S, Pereira I, Ram PT, Maxwell GL, Eberlin LS, Futreal PA, Bast RC Jr, Fleming ND, Conrads TP, Sood AK. Classification of High-Grade Serous Ovarian Cancer Using Tumor Morphologic Characteristics. JAMA Netw Open 5(10):e2236626, 2022. e-Pub 2022. PMID: 36239936.
51. Yap, TA, Ngoi, NY, Dumbrava, EE, Karp, DD, Rodon Ahnert, J, Fu, S, Hong, DS, Naing, A, Pant, S, Piha-Paul, SA, Subbiah, V, Tsimberidou, AM, Dufner, D, Rhudy, J, Gore, SD, Ivy, SP, Yuan, Y, Westin, SN, Mills, GB, Meric-Bernstam, F. Phase Ib Sequential Trial of Agents against DNA Repair (STAR) Study to investigate the sequential combination of the Poly (ADP-Ribose) Polymerase inhibitor (PARPi) olaparib (ola) and WEE1 inhibitor (WEE1i) adavosertib (ada) in patients (pts) with DNA Damage Response (DDR)-aberrant advanced tumors, enriched for BRCA1/2 mutated and CCNE1 amplified cancers. European Journal of Cancer 174:S7, 2022. e-Pub 2022.
52. Ngoi, NY, Pilie, PG, Piha-Paul, SA, Dumbrava, EE, Fu, S, Hong, DS, Karp, DD, Naing, A, Pant, S, Rodon Ahnert, J, Subbiah, V, Tsimberidou, AM, Salguero, C, Brown, CV, Hoadley, WE, Johnson, A, Yuan, Y, Westin, SN, Meric-Bernstam, F, Yap, TA. DNA Damage Response (DDR) Basket of Baskets (D-BOB) Trial. European Journal of Cancer 174:S10, 2022. e-Pub 2022.
53. Chu YY, Chen MK, Wei Y, Lee HH, Xia W, Wang YN, Yam C, Hsu JL, Wang HL, Chang WC, Yamaguchi H, Jiang Z, Liu C, Li CF, Nie L, Chan LC, Gao Y, Wang SC, Liu J, Westin SN, Lee S, Sood AK, Yang L, Hortobagyi GN, Yu D, Hung MC. Targeting the ALK-CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex. Nat Cancer 3(10):1211-1227, 2022. e-Pub 2022. PMID: 36253486.
54. Yeung AR, Deshmukh S, Klopp AH, Gil KM, Wenzel L, Westin SN, Konski AA, Gaffney DK, Small W Jr, Thompson JS, Doncals DE, Cantuaria GHC, D'Souza DP, Chang A, Kundapur V, Mohan DS, Haas ML, Kim YB, Ferguson CL, Pugh SL, Kachnic LA, Bruner DW. Intensity-Modulated Radiation Therapy Reduces Patient-Reported Chronic Toxicity Compared With Conventional Pelvic Radiation Therapy: Updated Results of a Phase III Trial. J Clin Oncol 40(27):3115-3119, 2022. e-Pub 2022. PMID: 35960897.
55. Zhao L, Corvigno S, Ma S, Celestino J, Fleming ND, Hajek RA, Lankenau Ahumada A, Jennings NB, Thompson EJ, Tang H, Westin SN, Jazaeri AA, Zhang J, Futreal PA, Sood AK, Lee S. Molecular Profiles of Serum-Derived Extracellular Vesicles in High-Grade Serous Ovarian Cancer. Cancers (Basel) 14(15), 2022. e-Pub 2022. PMID: 35892848.
56. Handley KF, Sood AK, Molin GZD, Westin SN, Meyer LA, Fellman B, Soliman PT, Coleman RL, Fleming ND. Frailty repels the knife: The impact of frailty index on surgical intervention and outcomes. Gynecol Oncol 166(1):50-56, 2022. e-Pub 2022. PMID: 35599168.
57. Gershenson DM, Sun CC, Westin SN, Eyada M, Cobb LP, Nathan LC, Sood AK, Malpica A, Hillman RT, Wong KK. The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes. Gynecol Oncol 165(3):560-567, 2022. e-Pub 2022. PMID: 35606067.
58. Vellano CP, White MG, Andrews MC, Chelvanambi M, Witt RG, Daniele JR, Titus M, McQuade JL, Conforti F, Burton EM, Lastrapes MJ, Ologun G, Cogdill AP, Morad G, Prieto P, Lazar AJ, Chu Y, Han G, Khan MAW, Helmink B, Davies MA, Amaria RN, Kovacs JJ, Woodman SE, Patel S, Hwu P, Peoples M, Lee JE, Cooper ZA, Zhu H, Gao G, Banerjee H, Lau M, Gershenwald JE, Lucci A, Keung EZ, Ross MI, Pala L, Pagan E, Segura RL, Liu Q, Borthwick MS, Lau E, Yates MS, Westin SN, Wani K, Tetzlaff MT, Haydu LE, Mahendra M, Ma X, Logothetis C, Kulstad Z, Johnson S, Hudgens CW, Feng N, Federico L, Long GV, Futreal PA, Arur S, Tawbi HA, Moran AE, Wang L, Heffernan TP, Marszalek JR, Wargo JA. Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature 606(7915):797-803, 2022. e-Pub 2022. PMID: 35705814.
59. Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi HA, Hwu P, Oliva ICG, Davies MA, Patel SP, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun 13(1):1970, 2022. e-Pub 2022. PMID: 35413951.
60. Stover EH, Xiong N, Myers AP, Tayob N, Engvold V, Polak M, Broaddus RR, Makker V, Drapkin R, Liu JF, Horowitz NS, Meric-Bernstam F, Aghajanian C, Coleman RL, Mills GB, Cantley LC, Matulonis UA, Westin SN, Konstantinopoulos PA. A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma. Gynecol Oncol Rep 40:100974, 2022. e-Pub 2022. PMID: 35434236.
61. LaFargue CJ, Handley KF, Fleming ND, Nick AM, Chelariu-Raicu A, Fellman B, Castellano T, Ogasawara A, Hom-Tedla M, Blake EA, da Costa AABA, Crim AK, Rauh-Hain A, Westin SN, Coleman RL, Matsuo K, Baiocchi G, Hasegawa K, Moore K, Sood AK. Clinical analysis of pathologic complete responders in advanced-stage ovarian cancer. Gynecol Oncol 165(1):82-89, 2022. e-Pub 2022. PMID: 35216808.
62. Westin SN. Should secondary cytoreduction be used in recurrent ovarian cancer?. Clin Adv Hematol Oncol 20(4):215-217, 2022. e-Pub 2022. PMID: 35389385.
63. Wu Y, Jennings NB, Sun Y, Dasari SK, Bayraktar E, Corvigno S, Stur E, Glassman D, Mangala LS, Lankenau Ahumada A, Westin SN, Sood AK, Hu W. Targeting CCR2(+) macrophages with BET inhibitor overcomes adaptive resistance to anti-VEGF therapy in ovarian cancer. J Cancer Res Clin Oncol 148(4):803-821, 2022. e-Pub 2022. PMID: 35094142.
64. Westin SN, Labrie M, Litton JK, Blucher A, Fang Y, Vellano CP, Marszalek JR, Feng N, Ma X, Creason A, Fellman B, Yuan Y, Lee S, Kim TB, Liu J, Chelariu-Raicu A, Chen TH, Kabil N, Soliman PT, Frumovitz M, Schmeler KM, Jazaeri A, Lu KH, Murthy R, Meyer LA, Sun CC, Sood AK, Coleman RL, Mills GB. Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. Clin Cancer Res 27(23):6354-6365, 2021. e-Pub 2021. PMID: 34518313.
65. Sun, H, Cao, S, Mashl, RJ, Mo, CK, Zaccaria, S, Wendl, MC, Davies, S, Bailey, MH, Primeau, T, Hoog, J, Mudd, JL, Dean, DA, Patidar, R, Chen, L, Wyczalkowski, MA, Jayasinghe, R, Rodrigues, FM, Terekhanova, NV, Li, Y, Lim, KH, Wang-Gillam, A, Van Tine, BA, Ma, C, Aft, R, Fuh, KC, Schwarz, JK, Roth, JA, Akcakanat, A, Chen, H, Dai, B, Gibbons, DL, Ha, MJ, Jensen, VB, Kim, M, Kopetz, S, Menter, DG, Meraz, I, Sorokin, A, Tapia, C, Wang, J, Westin, SN, Xi, Y, Yang, F, Yap, TA, Yennu Nanda, VG, Zhang, X, Zheng, X, Davies, MA, Fang, B, Meric-Bernstam, F. Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment. Nature communications 12(1), 2021. e-Pub 2021. PMID: 34429404.
66. Handley KF, Rodriguez-Aguayo C, Ma S, Stur E, Joseph R, Bayraktar E, Dasari SK, Nguyen N, Powell RT, Sobieski M, Ivan C, Kim M, Umamaheswaran S, Glassman D, Wen Y, Amero P, Stephan C, Coleman RL, Landesman Y, Westin SN, Ram PT, Sood AK. Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models. Mol Cancer Ther 20(12):2352-2361, 2021. e-Pub 2021. PMID: 34583979.
67. Monk BJ, Coleman RL, Fujiwara K, Wilson MK, Oza AM, Oaknin A, O'Malley DM, Lorusso D, Westin SN, Safra T, Herzog TJ, Marme F, N Eskander R, Lin KK, Shih D, Goble S, Grechko N, Hume S, Maloney L, McNeish IA, Kristeleit RS. ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer. Int J Gynecol Cancer 31(12):1589-1594, 2021. e-Pub 2021. PMID: 34593565.
68. Corvigno S, Burks JK, Hu W, Zhong Y, Jennings NB, Fleming ND, Westin SN, Fellman B, Liu J, Sood AK. Immune microenvironment composition in high-grade serous ovarian cancers based on BRCA mutational status. J Cancer Res Clin Oncol 147(12):3545-3555, 2021. e-Pub 2021. PMID: 34476576.
69. Westin SN, Louie-Gao M, Gupta D, Thaker PH. Risk factors for progression or death after first-line platinum-based chemotherapy in real-world patients in the USA with ovarian cancer from 2011 to 2018. Future Oncol 17(32):4263-4274, 2021. e-Pub 2021. PMID: 34378405.
70. How JA, Patel S, Fellman B, Lu KH, Hwu P, Ramondetta LM, Westin SN, Fleming ND, Soliman PT, Jazaeri AA. Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer. Gynecol Oncol 162(1):24-31, 2021. e-Pub 2021. PMID: 33958211.
71. Fleming ND, Westin SN, Rauh-Hain JA, Soliman PT, Fellman BM, Coleman RL, Meyer LA, Shafer A, Cobb LP, Jazaeri A, Lu KH, Sood AK. Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer. Gynecol Oncol 162(1):65-71, 2021. e-Pub 2021. PMID: 33838925.
72. Zhukovsky, DS, Haider, A, Williams, J, Naqvi, SM, Joshi, N, Mills, S, Soliman, PT, Mathew, B, Bodurka, DC, Meyer, LA, Westin, SN, Frumovitz, M, Nowitz, M, Archie, LS, Fenton, SL, Lang, K, Boving, VG, Bruera, E. An Integrated Approach to Selecting a Prepared Medical Decision-Maker. Journal of pain and symptom management 61(6):1305-1310, 2021. e-Pub 2021. PMID: 33348030.
73. How JA, Jazaeri A, Westin SN, Sood AK, Ramondetta LM, Xu M, Abonofal A, Karp DD, Subbiah V, Stephen B, Rodon JA, Yang F, Naing A. The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial. Invest New Drugs 39(3):829-835, 2021. e-Pub 2021. PMID: 33415580.
74. Yao S, Janku F, Subbiah V, Stewart J, Patel SP, Kaseb A, Westin SN, Naing A, Tsimberidou AM, Hong D, Piha-Paul SA, Shi N, Johnston A, Bomalaski J, Fu S. Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies. Br J Cancer 124(9):1533-1539, 2021. e-Pub 2021. PMID: 33674736.
75. Harrison RF, Cantor SB, Sun CC, Villanueva M, Westin SN, Fleming ND, Toumazis I, Sood AK, Lu KH, Meyer LA. Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer. Gynecol Oncol 161(1):56-62, 2021. e-Pub 2021. PMID: 33536126.
76. Coleman RL, Hu W, Soliman P, Nick A, Ramirez PT, Westin SN, Garcia ME, Zhu Z, Palancia J, Fellman BM, Yuan Y, Ram P, Bischoff F, Schmeler K, Bodurka D, Meyer LA, Sood AK. Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study. Gynecol Oncol 161(1):104-112, 2021. e-Pub 2021. PMID: 33551196.
77. Siedel JH, Ring KL, Hu W, Dood RL, Wang Y, Baggerly K, Darcy KM, Conrads TP, Gallagher S, Tshiaba P, Neff C, Timms KM, Mangala S, Westin SN, Broaddus R, Lopez-Berestein G, Lu KH, Coleman RL, Maxwell GL, Sood AK. Clinical significance of homologous recombination deficiency score testing in endometrial Cancer. Gynecol Oncol 160(3):777-785, 2021. e-Pub 2021. PMID: 33563487.
78. Lee S, Zhao L, Little LD, Westin SN, Jazarei AA, Fleming ND, Zhang J, Futreal PA, Sood AK. Distinct T cell receptor repertoire diversity of clinically defined high-grade serous ovarian cancer treatment subgroups. iScience 24(2):102053, 2021. e-Pub 2021. PMID: 33537658.
79. Zhong Y, Liu J, Li X, Westin SN, Malpica A, Lawson BC, Lee S, Fellman BM, Coleman RL, Sood AK, Fleming ND. A Modified 2 Tier Chemotherapy Response Score (CRS) and Other Histopathologic Features for Predicting Outcomes of Patients with Advanced Extrauterine High-Grade Serous Carcinoma after Neoadjuvant Chemotherapy. Cancers (Basel) 13(4), 2021. e-Pub 2021. PMID: 33572451.
80. Westin SN, Fellman B, Sun CC, Broaddus RR, Woodall ML, Pal N, Urbauer DL, Ramondetta LM, Schmeler KM, Soliman PT, Fleming ND, Burzawa JK, Nick AM, Milbourne AM, Yuan Y, Lu KH, Bodurka DC, Coleman RL, Yates MS. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer. Am J Obstet Gynecol 224(2):191.e1-191.e15, 2021. e-Pub 2021. PMID: 32805208.
81. Bailey CD, Previs R, Fellman BM, Zaid T, Huang M, Brown A, Enbaya A, Balakrishnan N, Broaddus RR, Bodurka DC, Soliman P, Fleming ND, Nick A, Sood AK, Westin SN. Pathologic distribution at the time of interval tumor reductive surgery informs personalized surgery for high-grade ovarian cancer. Int J Gynecol Cancer 31(2):232-237, 2021. e-Pub 2021. PMID: 33122243.
82. Fleming ND, Westin SN, Meyer LA, Shafer A, Rauh-Hain JA, Onstad M, Cobb L, Bevers M, Fellman BM, Burzawa J, Bhosale P, Zand B, Jazaeri A, Levenback C, Coleman RL, Soliman PT, Sood AK. Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer. Int J Gynecol Cancer 31(1):92-97, 2021. e-Pub 2021. PMID: 33154095.
83. Tew WP, Lacchetti C, Ellis A, Maxian K, Banerjee S, Bookman M, Jones MB, Lee JM, Lheureux S, Liu JF, Moore KN, Muller C, Rodriguez P, Walsh C, Westin SN, Kohn EC. PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline. J Clin Oncol 38(30):3468-3493, 2020. e-Pub 2020. PMID: 32790492.
84. Frumovitz M, Westin SN, Salvo G, Zarifa A, Xu M, Yap TA, Rodon AJ, Karp DD, Abonofal A, Jazaeri AA, Naing A. Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract. Gynecol Oncol 158(3):570-575, 2020. e-Pub 2020. PMID: 32534809.
85. Cobb LP, Sun CC, Iyer R, Nick AM, Fleming ND, Westin SN, Sood AK, Wong KK, Silva EG, Gershenson DM. The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance. Gynecol Oncol 158(3):653-658, 2020. e-Pub 2020. PMID: 32709538.
86. Myers AP, Konstantinopoulos PA, Barry WT, Luo W, Broaddus RR, Makker V, Drapkin R, Liu J, Doyle A, Horowitz NS, Meric-Bernstam F, Birrer M, Aghajanian C, Coleman RL, Mills GB, Cantley LC, Matulonis UA, Westin SN. Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer. Int J Cancer 147(2):413-422, 2020. e-Pub 2020. PMID: 31714586.
87. Kim KH, Moore KN, Arend RC, Bakkum-Gamez JN, Westin SN. The 2020 SGO Annual Meeting Report. Gynecol Oncol 158(1):12-15, 2020. e-Pub 2020. PMID: 32487447.
88. Pothuri B, Alvarez Secord A, Armstrong DK, Chan J, Fader AN, Huh W, Kesterson J, Liu JF, Moore K, Westin SN, Naumann RW. Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis. Gynecol Oncol 158(1):16-24, 2020. e-Pub 2020. PMID: 32386911.
89. Obermair A, Baxter E, Brennan DJ, McAlpine JN, Muellerer JJ, Amant F, van Gent MDJM, Coleman RL, Westin SN, Yates MS, Krakstad C, Janda M. Fertility-sparing treatment in early endometrial cancer: current state and future strategies. Obstet Gynecol Sci 63(4):417-431, 2020. e-Pub 2020. PMID: 32689770.
90. Yeung AR, Pugh SL, Klopp AH, Gil KM, Wenzel L, Westin SN, Gaffney DK, Small W Jr, Thompson S, Doncals DE, Cantuaria GHC, Yaremko BP, Chang A, Kundapur V, Mohan DS, Haas ML, Kim YB, Ferguson CL, Deshmukh S, Bruner DW, Kachnic LA. Improvement in Patient-Reported Outcomes With Intensity-Modulated Radiotherapy (RT) Compared With Standard RT: A Report From the NRG Oncology RTOG 1203 Study. J Clin Oncol 38(15):1685-1692, 2020. e-Pub 2020. PMID: 32073955.
91. Lee S, Zhao L, Rojas C, Bateman NW, Yao H, Lara OD, Celestino J, Morgan MB, Nguyen TV, Conrads KA, Rangel KM, Dood RL, Hajek RA, Fawcett GL, Chu RA, Wilson K, Loffredo JL, Viollet C, Jazaeri AA, Dalgard CL, Mao X, Song X, Zhou M, Hood BL, Banskota N, Wilkerson MD, Te J, Soltis AR, Roman K, Dunn A, Cordover D, Eterovic AK, Liu J, Burks JK, Baggerly KA, Fleming ND, Lu KH, Westin SN, Coleman RL, Mills GB, Casablanca Y, Zhang J, Conrads TP, Maxwell GL, Futreal PA, Sood AK. Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer. Cell Rep 31(2):107502, 2020. e-Pub 2020. PMID: 32294438.
92. Markham MJ, Wachter K, Agarwal N, Bertagnolli MM, Chang SM, Dale W, Diefenbach CSM, Rodriguez-Galindo C, George DJ, Gilligan TD, Harvey RD, Johnson ML, Kimple RJ, Knoll MA, LoConte N, Maki RG, Meisel JL, Meyerhardt JA, Pennell NA, Rocque GB, Sabel MS, Schilsky RL, Schneider BJ, Tap WD, Uzzo RG, Westin SN. Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol 38(10):1081, 2020. e-Pub 2020. PMID: 32013670.
93. Berg HF, Ju Z, Myrvold M, Fasmer KE, Halle MK, Hoivik EA, Westin SN, Trovik J, Haldorsen IS, Mills GB, Krakstad C, Werner HMJ. Development of prediction models for lymph node metastasis in endometrioid endometrial carcinoma. Br J Cancer 122(7):1014-1022, 2020. e-Pub 2020. PMID: 32037399.
94. Stewart KI, Eska JS, Harrison RF, Suidan R, Abraham A, Chisholm GB, Meyer LA, Westin SN, Fleming ND, Frumovitz M, Aloia TA, Soliman PT. Implementation of a sentinel lymph node mapping algorithm for endometrial cancer: surgical outcomes and hospital charges. Int J Gynecol Cancer 30(3):352-357, 2020. e-Pub 2020. PMID: 31911539.
95. Lakomy DS, Urbauer DL, Westin SN, Lin LL. Phase I study of the PARP inhibitor talazoparib with radiation therapy for locally recurrent gynecologic cancers. Clin Transl Radiat Oncol 21:56-61, 2020. e-Pub 2020. PMID: 31993510.
96. Soliman PT, Westin SN, Iglesias DA, Fellman BM, Yuan Y, Zhang Q, Yates MS, Broaddus RR, Slomovitz BM, Lu KH, Coleman RL. Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study. Clin Cancer Res 26(3):581-587, 2020. e-Pub 2020. PMID: 31628143.
97. Harrison R, Zhao H, Sun CC, Fu S, Armbruster SD, Westin SN, Rauh-Hain JA, Lu KH, Giordano SH, Meyer LA. Body mass index and attitudes towards health behaviors among women with endometrial cancer before and after treatment. Int J Gynecol Cancer 30(2):187-192, 2020. e-Pub 2020. PMID: 31843871.
98. Zibetti Dal Molin G, Westin SN, Msaouel P, Gomes LM, Dickens A, Coleman RL. Discrepancy in calculated and measured glomerular filtration rates in patients treated with PARP inhibitors. Int J Gynecol Cancer 30(1):89-93, 2020. e-Pub 2020. PMID: 31792084.
99. Westin SN, Sill MW, Coleman RL, Waggoner S, Moore KN, Mathews CA, Martin LP, Modesitt SC, Lee S, Ju Z, Mills GB, Schilder RJ, Fracasso PM, Birrer MJ, Aghajanian C. Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study. Gynecol Oncol 155(3):420-428, 2019. e-Pub 2019. PMID: 31623857.
100. Gallagher JR, Heap KJ, Carroll S, Travers K, Harrow B, Westin SN. Real-world adverse events with niraparib 200 mg/day maintenance therapy in ovarian cancer: a retrospective study. Future Oncol 15(36):4197-4206, 2019. e-Pub 2019. PMID: 31707856.
101. Lara OD, Krishnan S, Wang Z, Corvigno S, Zhong Y, Lyons Y, Dood R, Hu W, Qi L, Liu J, Coleman RL, Westin SN, Fleming ND, Cristini V, Rao A, Burks J, Sood AK. Tumor core biopsies adequately represent immune microenvironment of high-grade serous carcinoma. Sci Rep 9(1):17589, 2019. e-Pub 2019. PMID: 31772388.
102. Harrison RF, He W, Fu S, Zhao H, Sun CC, Suidan RS, Woodard TL, Rauh-Hain JA, Westin SN, Giordano SH, Meyer LA. National patterns of care and fertility outcomes for reproductive-aged women with endometrial cancer or atypical hyperplasia. Am J Obstet Gynecol 221(5):474.e1-474.e11, 2019. e-Pub 2019. PMID: 31128110.
103. Stewart KI, Chasen B, Erwin W, Fleming N, Westin SN, Dioun S, Frumovitz M, Ramirez PT, Lu KH, Wong F, Aloia TA, Soliman PT. Preoperative PET/CT does not accurately detect extrauterine disease in patients with newly diagnosed high-risk endometrial cancer: A prospective study. Cancer 125(19):3347-3353, 2019. e-Pub 2019. PMID: 31225906.
104. Ramondetta LM, Hu W, Thaker PH, Urbauer DL, Chisholm GB, Westin SN, Sun Y, Ramirez PT, Fleming N, Sahai SK, Nick AM, Arevalo JMG, Dizon T, Coleman RL, Cole SW, Sood AK. Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression. Gynecol Oncol 154(3):524-530, 2019. e-Pub 2019. PMID: 31353053.
105. Armbruster SD, Previs R, Soliman PT, Westin SN, Fellman B, Jhingran A, Fleming ND. Clinicopathologic features and treatment in patients with early stage uterine clear cell carcinoma: A 16-year experience. Gynecol Oncol 154(2):328-332, 2019. e-Pub 2019. PMID: 31221496.
106. Vreeland TJ, Beaudry Simoneau E, Dewhurst WL, Newhook TE, Westin SN, Mehran RJ, Chun YS, Aloia TA, Vauthey JN, Tzeng CD. Intraoperative Air Leak Test to Prevent Bile Leak After Right Posterior Sectionectomy with En Bloc Diaphragm Resection for Metastatic Teratoma. Ann Surg Oncol 26(8):2579, 2019. e-Pub 2019. PMID: 31065963.
107. Kurnit KC, Westin SN, Coleman RL. Microsatellite instability in endometrial cancer: New purpose for an old test. Cancer 125(13):2154-2163, 2019. e-Pub 2019. PMID: 30913308.
108. Gil KM, Pugh SL, Klopp AH, Yeung AR, Wenzel L, Westin SN, Gaffney DK, Small W Jr, Thompson S, Doncals DE, Cantuaria GHC, Yaremko BP, Chang A, Kundapur V, Mohan DS, Haas ML, Kim YB, Ferguson CL, Deshmukh S, Kachnic LA, Bruner DW. Expanded validation of the EPIC bowel and urinary domains for use in women with gynecologic cancer undergoing postoperative radiotherapy. Gynecol Oncol 154(1):183-188, 2019. e-Pub 2019. PMID: 31104905.
109. Chapman BV, Swanick CW, Ning MS, Allen PK, Soliman PT, Westin SN, Pardeshi V, Broaddus RR, Lu KH, Jhingran A, Eifel PJ, Klopp AH. Adjuvant combined-modality therapy for stage IIIC endometrioid and non-endometrioid endometrial cancer. Gynecol Oncol 154(1):22-28, 2019. e-Pub 2019. PMID: 31109659.
110. Kurnit KC, Lu KH, Westin SN. Rapidly Changing Landscape of Fallopian Tube Carcinoma. J Oncol Pract 15(7):383-384, 2019. e-Pub 2019. PMID: 31283416.
111. Fang Y, McGrail DJ, Sun C, Labrie M, Chen X, Zhang D, Ju Z, Vellano CP, Lu Y, Li Y, Jeong KJ, Ding Z, Liang J, Wang SW, Dai H, Lee S, Sahni N, Mercado-Uribe I, Kim TB, Chen K, Lin SY, Peng G, Westin SN, Liu J, O'Connor MJ, Yap TA, Mills GB. Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy. Cancer Cell 35(6):851-867.e7, 2019. e-Pub 2019. PMID: 31185210.
112. Labrie M, Kim TB, Ju Z, Lee S, Zhao W, Fang Y, Lu Y, Chen K, Ramirez P, Frumovitz M, Meyer L, Fleming ND, Sood AK, Coleman RL, Mills GB, Westin SN. Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options. Oncotarget 10(37):3533-3546, 2019. e-Pub 2019. PMID: 31191824.
113. Hinchcliff E, Westin SN, Dal Molin G, LaFargue CJ, Coleman RL. Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: expanding indications and novel combination strategies. Int J Gynecol Cancer, 2019. e-Pub 2019. PMID: 31118216.
114. Pal SK, Miller MJ, Agarwal N, Chang SM, Chavez-MacGregor M, Cohen E, Cole S, Dale W, Magid Diefenbach CS, Disis ML, Dreicer R, Graham DL, Henry NL, Jones J, Keedy V, Klepin HD, Markham MJ, Mittendorf EA, Rodriguez-Galindo C, Sabel MS, Schilsky RL, Sznol M, Tap WD, Westin SN, Johnson BE. Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol 37(10):834-849, 2019. e-Pub 2019. PMID: 30702028.
115. Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Cadoo KA, Shapiro GI, Mayer EL, O'Cearbhaill RE, Coleman RL, Kochupurakkal B, Whalen C, Curtis J, Farooq S, Luo W, Eismann J, Buss MK, Aghajanian C, Mills GB, Palakurthi S, Kirschmeier P, Liu J, Cantley LC, Kaufmann SH, Swisher EM, D'Andrea AD, Winer E, Wulf GM, Matulonis UA. Olaparib and alpha-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncol 20(4):570-580, 2019. e-Pub 2019. PMID: 30880072.
116. Kurnit KC, Previs RA, Soliman PT, Westin SN, Klopp AH, Fellman BM, Lu KH, Ramondetta LM, Fleming ND. Prognostic factors impacting survival in early stage uterine carcinosarcoma. Gynecol Oncol 152(1):31-37, 2019. e-Pub 2019. PMID: 30414738.
117. Hansen JM, Sood AK, Coleman RL, Westin SN, Soliman PT, Ramirez PT, Fellman BM, Schmeler KM, Fleming ND. Concordance of a laparoscopic scoring algorithm with primary surgery findings in advanced stage ovarian cancer. Gynecol Oncol 151(3):428-432, 2018. e-Pub 2018. PMID: 30366647.
118. Bruinooge S, Pickard TA, Vogel W, Hanley A, Schenkel C, Garrett-Mayer E, Tetzlaff E, Rosenzweig M, Hylton H, Westin SN, Smith N, Lynch C, Kosty MP, Williams SF. Understanding the Role of Advanced Practice Providers in Oncology in the United States. Oncol Nurs Forum 45(6):786-800, 2018. e-Pub 2018. PMID: 30339144.
119. Dood RL, Fleming ND, Coleman RL, Westin SN, Lara OD, LaFargue CJ, Liu J, Sood AK. When Ovarian Cancer Is Not: Characterizing Nonovarian Cancer Pathology in a Laparoscopy-Based Triage System. Int J Gynecol Cancer 28(8):1485-1490, 2018. e-Pub 2018. PMID: 30036226.
120. Bruinooge SS, Pickard TA, Vogel W, Hanley A, Schenkel C, Garrett-Mayer E, Tetzlaff E, Rosenzweig M, Hylton H, Westin SN, Smith N, Lynch C, Kosty MP, Williams SF. Understanding the Role of Advanced Practice Providers in Oncology in the United States. J Oncol Pract 14(9):e518-e532, 2018. e-Pub 2018. PMID: 30133346.
121. Jalloul RJ, Nick AM, Munsell MF, Westin SN, Ramirez PT, Frumovitz M, Soliman PT. The influence of surgeon volume on outcomes after pelvic exenteration for a gynecologic cancer. J Gynecol Oncol 29(5):e68, 2018. e-Pub 2018. PMID: 30022632.
122. Fleming ND, Nick AM, Coleman RL, Westin SN, Ramirez PT, Soliman PT, Fellman B, Meyer LA, Schmeler KM, Lu KH, Sood AK. Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer. Obstet Gynecol 132(3):545-554, 2018. e-Pub 2018. PMID: 30095787.
123. Klopp AH, Yeung AR, Deshmukh S, Gil KM, Wenzel L, Westin SN, Gifford K, Gaffney DK, Small W Jr, Thompson S, Doncals DE, Cantuaria GHC, Yaremko BP, Chang A, Kundapur V, Mohan DS, Haas ML, Kim YB, Ferguson CL, Pugh SL, Kachnic LA, Bruner DW. Patient-Reported Toxicity During Pelvic Intensity-Modulated Radiation Therapy: NRG Oncology-RTOG 1203. J Clin Oncol 36(24):2538-2544, 2018. e-Pub 2018. PMID: 29989857.
124. Nishio S, Matsuo K, Yonemoto K, Shimokawa M, Hosaka M, Kodama M, Miyake TM, Ushijima K, Kamura T, Westin SN, Soliman PT, Coleman RL. Race and nodal disease status are prognostic factors in patients with stage IVB cervical cancer. Oncotarget 9(64):32321-32330, 2018. e-Pub 2018. PMID: 30190789.
125. Suidan RS, Sun CC, Cantor SB, Mariani A, Soliman PT, Westin SN, Lu KH, Giordano SH, Meyer LA. Three Lymphadenectomy Strategies in Low-Risk Endometrial Carcinoma: A Cost-Effectiveness Analysis. Obstet Gynecol 132(1):52-58, 2018. e-Pub 2018. PMID: 29889752.
126. Armbruster SD, Sun CC, Westin SN, Bodurka DC, Ramondetta L, Meyer LA, Soliman PT. Prospective assessment of patient-reported outcomes in gynecologic cancer patients before and after pelvic exenteration. Gynecol Oncol 149(3):484-490, 2018. e-Pub 2018. PMID: 29622276.
127. Banerji U, Dean EJ, Perez-Fidalgo JA, Batist G, Bedard PL, You B, Westin SN, Kabos P, Garrett MD, Tall M, Ambrose H, Barrett JC, Carr TH, Cheung SYA, Corcoran C, Cullberg M, Davies BR, de Bruin EC, Elvin P, Foxley A, Lawrence P, Lindemann JPO, Maudsley R, Pass M, Rowlands V, Rugman P, Schiavon G, Yates J, Schellens JHM. A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers. Clin Cancer Res 24(9):2050-2059, 2018. e-Pub 2018. PMID: 29066505.
128. Heymach J, Krilov L, Alberg A, Baxter N, Chang SM, Corcoran RB, Dale W, DeMichele A, Magid Diefenbach CS, Dreicer R, Epstein AS, Gillison ML, Graham DL, Jones J, Ko AH, Lopez AM, Maki RG, Rodriguez-Galindo C, Schilsky RL, Sznol M, Westin SN, Burstein H. Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol 36(10):1020-1044, 2018. e-Pub 2018. PMID: 29380678.
129. Pal N, Broaddus RR, Urbauer DL, Balakrishnan N, Milbourne A, Schmeler KM, Meyer LA, Soliman PT, Lu KH, Ramirez PT, Ramondetta L, Bodurka DC, Westin SN. Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device. Obstet Gynecol 131(1):109-116, 2018. e-Pub 2018. PMID: 29215513.
130. Mauland KK, Ju Z, Tangen IL, Berg A, Kalland KH, Oyan AM, Bjorge L, Westin SN, Krakstad C, Trovik J, Mills GB, Hoivik EA, Johanna Werner HM. Proteomic profiling of endometrioid endometrial cancer reveals differential expression of hormone receptors and MAPK signaling proteins in obese versus non-obese patients. Oncotarget 8(63):106989-107001, 2017. e-Pub 2017. PMID: 29291005.
131. Fleming ND, Coleman RL, Tung C, Westin SN, Hu W, Sun Y, Bhosale P, Munsell MF, Sood AK. Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer. Gynecol Oncol 147(1):41-46, 2017. e-Pub 2017. PMID: 28774461.
132. Soliman PT, Westin SN, Dioun S, Sun CC, Euscher E, Munsell MF, Fleming ND, Levenback C, Frumovitz M, Ramirez PT, Lu KH. A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer. Gynecol Oncol 146(2):234-239, 2017. e-Pub 2017. PMID: 28528918.
133. Khafagy AM, Prescott LS, Malpica A, Westin SN. Unusual indolent behavior of leiomyosarcoma of the vagina: Is observation a viable option?. Gynecol Oncol Rep 21:28-30, 2017. e-Pub 2017. PMID: 28649595.
134. Bednar EM, Oakley HD, Sun CC, Burke CC, Munsell MF, Westin SN, Lu KH. A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment. Gynecol Oncol 146(2):399-404, 2017. e-Pub 2017. PMID: 28610746.
135. Newtson AM, Pakish JB, Nick AM, Westin SN. Dual progestin therapy for fertility-sparing treatment of grade 2 endometrial adenocarcinoma. Gynecol Oncol Rep 21:117-118, 2017. e-Pub 2017. PMID: 28831417.
136. Hyman DM, Smyth LM, Donoghue MTA, Westin SN, Bedard PL, Dean EJ, Bando H, El-Khoueiry AB, Perez-Fidalgo JA, Mita A, Schellens JHM, Chang MT, Reichel JB, Bouvier N, Selcuklu SD, Soumerai TE, Torrisi J, Erinjeri JP, Ambrose H, Barrett JC, Dougherty B, Foxley A, Lindemann JPO, McEwen R, Pass M, Schiavon G, Berger MF, Chandarlapaty S, Solit DB, Banerji U, Baselga J, Taylor BS. AKT Inhibition in Solid Tumors With AKT1 Mutations. J Clin Oncol 35(20):2251-2259, 2017. e-Pub 2017. PMID: 28489509.
137. Holman LL, Pal N, Iglesias DA, Soliman PT, Balakrishnan N, Klopp A, Broaddus RR, Fleming ND, Munsell MF, Lu KH, Westin SN. Factors prognostic of survival in advanced-stage uterine serous carcinoma. Gynecol Oncol 146(1):27-33, 2017. e-Pub 2017. PMID: 28465008.
138. Euscher E, Sui D, Soliman P, Westin S, Ramalingam P, Bassett R, Malpica A. Ultrastaging of Sentinel Lymph Nodes in Endometrial Carcinoma According to Use of 2 Different Methods. Int J Gynecol Pathol. e-Pub 2017. PMID: 28700425.
139. Sun C, Fang Y, Yin J, Chen J, Ju Z, Zhang D, Chen X, Vellano CP, Jeong KJ, Ng PK, Eterovic AKB, Bhola NH, Lu Y, Westin SN, Grandis JR, Lin SY, Scott KL, Peng G, Brugge J, Mills GB. Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers. Sci Transl Med 9(392), 2017. e-Pub 2017. PMID: 28566428.
140. Suidan RS, He W, Sun CC, Zhao H, Fleming ND, Ramirez PT, Soliman PT, Westin SN, Lu KH, Giordano SH, Meyer LA. Impact of body mass index and operative approach on surgical morbidity and costs in women with endometrial carcinoma and hyperplasia. Gynecol Oncol 145(1):55-60, 2017. e-Pub 2017. PMID: 28131529.
141. Matulonis UA, Wulf GM, Barry WT, Birrer M, Westin SN, Farooq S, Bell-McGuinn KM, Obermayer E, Whalen C, Spagnoletti T, Luo W, Liu H, Hok RC, Aghajanian C, Solit DB, Mills GB, Taylor BS, Won H, Berger MF, Palakurthi S, Liu J, Cantley LC, Winer E. Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer. Ann Oncol 28(3):512-518, 2017. e-Pub 2017. PMID: 27993796.
142. Fleming ND, Ramirez PT, Soliman PT, Schmeler KM, Chisholm GB, Nick AM, Westin SN, Frumovitz M. Quality of life after radical trachelectomy for early-stage cervical cancer: A 5-year prospective evaluation. Gynecol Oncol 143(3):596-603, 2016. e-Pub 2016. PMID: 27742473.
143. Soliman PT, Zhang Q, Broaddus RR, Westin SN, Iglesias D, Munsell MF, Schmandt R, Yates M, Ramondetta L, Lu KH. Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer: A window of opportunity study. Gynecol Oncol 143(3):466-471, 2016. e-Pub 2016. PMID: 27745917.
144. Goldstein J, Pandey P, Fleming N, Westin S, Piha-Paul S. A non-pregnant woman with elevated beta-HCG: A case of para-neoplastic syndrome in ovarian cancer. Gynecol Oncol Rep 17:49-52, 2016. e-Pub 2016. PMID: 27355002.
145. Hou MM, Wang Z, Janku F, Piha-Paul S, Naing A, Hong D, Westin S, Coleman RL, Sood AK, Tsimberidou AM, Subbiah V, Wheler J, Zinner R, Lu K, Meric-Bernstam F, Fu S. Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. Oncotarget 7(23):35132-43, 2016. e-Pub 2016. PMID: 27147567.
146. Westin SN, Sun CC, Tung CS, Lacour RA, Meyer LA, Urbauer DL, Frumovitz MM, Lu KH, Bodurka DC. Survivors of gynecologic malignancies: impact of treatment on health and well-being. J Cancer Surviv 10(2):261-70, 2016. e-Pub 2016. PMID: 26245979.
147. Westin SN, Randall L. The European Society of Gynecologic Oncology (ESGO) 19th biannual meeting: Overview and summary of selected topics. Gynecol Oncol 140(3):377-80, 2016. e-Pub 2016. PMID: 26807487.
148. Yang JY, Werner HM, Li J, Westin SN, Lu Y, Halle MK, Trovik J, Salvesen HB, Mills GB, Liang H. Integrative Protein-Based Prognostic Model for Early-Stage Endometrioid Endometrial Cancer. Clin Cancer Res 22(2):513-23, 2016. e-Pub 2016. PMID: 26224872.
149. Subbiah V, Wagner MJ, McGuire MF, Sarwari NM, Devarajan E, Lewis VO, Westin S, Kato S, Brown RE, Anderson P. Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine. Oncotarget 6(38):40642-54, 2015. e-Pub 2015. PMID: 26510912.
150. Holman LL, Ren Y, Westin SN. Status epilepticus associated with platinum chemotherapy in a patient with cervical cancer: a case report. BMC Cancer 15:728, 2015. e-Pub 2015. PMID: 26474752.
151. Ho JC, Allen PK, Jhingran A, Westin SN, Lu KH, Eifel PJ, Klopp AH. Management of nodal recurrences of endometrial cancer with IMRT. Gynecol Oncol 139(1):40-6, 2015. e-Pub 2015. PMID: 26193429.
152. Westin SN, Ju Z, Broaddus RR, Krakstad C, Li J, Pal N, Lu KH, Coleman RL, Hennessy BT, Klempner SJ, Werner HM, Salvesen HB, Cantley LC, Mills GB, Myers AP. PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients. Mol Oncol 9(8):1694-703, 2015. e-Pub 2015. PMID: 26045339.
153. Fleming ND, Soliman PT, Westin SN, dos Reis R, Munsell M, Klopp AH, Frumovitz M, Nick AM, Schmeler K, Ramirez PT. Impact of Lymph Node Ratio and Adjuvant Therapy in Node-Positive Endometrioid Endometrial Cancer. Int J Gynecol Cancer 25(8):1437-44, 2015. e-Pub 2015. PMID: 26332387.
154. dos Reis R, Burzawa JK, Tsunoda AT, Hosaka M, Frumovitz M, Westin SN, Munsell MF, Ramirez PT. Lymphovascular Space Invasion Portends Poor Prognosis in Low-Risk Endometrial Cancer. Int J Gynecol Cancer 25(7):1292-9, 2015. e-Pub 2015. PMID: 26067863.
155. Arms III RG, Sun CC, Burzawa JK, Fleming ND, Nick AM, Rallapalli V, Westin SN, Meyer LA, Ramirez PT, Soliman PT. Improvement in quality of life after robotic surgery results in patient satisfaction. Gynecol Oncol 138(3):727-30, 2015. e-Pub 2015. PMID: 26197762.
156. Fleming ND, Frumovitz M, Schmeler KM, dos Reis R, Munsell MF, Eifel PJ, Soliman PT, Nick AM, Westin SN, Ramirez PT. Significance of lymph node ratio in defining risk category in node-positive early stage cervical cancer. Gynecol Oncol 136(1):48-53, 2015. e-Pub 2015. PMID: 25451695.
157. Costales AB, Schmeler KM, Broaddus R, Soliman PT, Westin SN, Ramirez PT, Frumovitz M. Clinically significant endometrial cancer risk following a diagnosis of complex atypical hyperplasia. Gynecol Oncol 135(3):451-4, 2014. e-Pub 2014. PMID: 25316176.
158. Ulm MA, Fleming ND, Rallapali V, Munsell MF, Ramirez PT, Westin SN, Nick AM, Schmeler KM, Soliman PT. Position-related injury is uncommon in robotic gynecologic surgery. Gynecol Oncol 135(3):534-8, 2014. e-Pub 2014. PMID: 25449565.
159. Carroll A, Ramirez PT, Westin SN, Soliman PT, Munsell MF, Nick AM, Schmeler KM, Klopp AH, Fleming ND. Uterine adenosarcoma: an analysis on management, outcomes, and risk factors for recurrence. Gynecol Oncol 135(3):455-61, 2014. e-Pub 2014. PMID: 25449308.
160. Brana I, Berger R, Golan T, Haluska P, Edenfield J, Fiorica J, Stephenson J, Martin LP, Westin S, Hanjani P, Jones MB, Almhanna K, Wenham RM, Sullivan DM, Dalton WS, Gunchenko A, Cheng JD, Siu LL, Gray JE. A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours. Br J Cancer 111(10):1932-44, 2014. e-Pub 2014. PMID: 25290091.
161. Westin SN, Rallapalli V, Fellman B, Urbauer DL, Pal N, Frumovitz MM, Ramondetta LM, Bodurka DC, Ramirez PT, Soliman PT. Overall survival after pelvic exenteration for gynecologic malignancy. Gynecol Oncol 134(3):546-51, 2014. e-Pub 2014. PMID: 25014540.
162. Slaughter KN, Frumovitz M, Schmeler KM, Nick AM, Fleming ND, dos Reis R, Munsell MF, Westin SN, Soliman PT, Ramirez PT. Minimally invasive surgery for endometrial cancer: does operative start time impact surgical and oncologic outcomes?. Gynecol Oncol 134(2):248-52, 2014. e-Pub 2014. PMID: 24945591.
163. Jones N, Fleming ND, Nick AM, Munsell MF, Rallapalli V, Westin SN, Meyer LA, Schmeler KM, Ramirez PT, Soliman PT. Conversion from robotic surgery to laparotomy: a case-control study evaluating risk factors for conversion. Gynecol Oncol 134(2):238-42, 2014. e-Pub 2014. PMID: 24937481.
164. Rauch GM, Kaur H, Choi H, Ernst RD, Klopp AH, Boonsirikamchai P, Westin SN, Marcal LP. Optimization of MR imaging for pretreatment evaluation of patients with endometrial and cervical cancer. Radiographics 34(4):1082-98, 2014. e-Pub 2014. PMID: 25019443.
165. Meyer LA, Slomovitz BM, Djordjevic B, Westin SN, Iglesias DA, Munsell MF, Jiang Y, Schmandt R, Broaddus RR, Coleman RL, Galbincea JM, Lu KH. The search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancer. Int J Gynecol Cancer 24(4):713-7, 2014. e-Pub 2014. PMID: 24651628.
166. Pakish J, Soliman PT, Frumovitz M, Westin SN, Schmeler KM, Reis RD, Munsell MF, Ramirez PT. A comparison of extraperitoneal versus transperitoneal laparoscopic or robotic para-aortic lymphadenectomy for staging of endometrial carcinoma. Gynecol Oncol 132(2):366-71, 2014. e-Pub 2014. PMID: 24361579.
167. Subbiah V, Westin SN, Wang K, Araujo D, Wang WL, Miller VA, Ross JS, Stephens PJ, Palmer GA, Ali SM. Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein. J Hematol Oncol 7:8, 2014. e-Pub 2014. PMID: 24422672.
168. Huang M, Iglesias DA, Westin SN, Fellman B, Urbauer D, Schmeler KM, Frumovitz M, Ramirez PT, Soliman PT. Pelvic exenteration: impact of age on surgical and oncologic outcomes. Gynecol Oncol 132(1):114-8, 2014. e-Pub 2014. PMID: 24262877.
169. Tang C, Jardim DL, Falchook GS, Hess K, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, De Melo Galgiato D, Westin SN, Meric-Bernstam F, Kurzrock R, Hong DS. MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors. Oncoscience 1(1):5-13, 2014. e-Pub 2014. PMID: 25593979.
170. Bruegl AS, Djordjevic B, Urbauer DL, Westin SN, Soliman PT, Lu KH, Luthra R, Broaddus RR. Utility of MLH1 methylation analysis in the clinical evaluation of Lynch Syndrome in women with endometrial cancer. Curr Pharm Des 20(11):1655-63, 2014. e-Pub 2014. PMID: 23888949.
171. Jardim DL, Wheler JJ, Hess K, Tsimberidou AM, Zinner R, Janku F, Subbiah V, Naing A, Piha-Paul SA, Westin SN, Roy-Chowdhuri S, Meric-Bernstam F, Hong DS. FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors. PLoS One 9(2):e89388, 2014. e-Pub 2014. PMID: 24586741.
172. Soliman PT, Iglesias D, Munsell MF, Frumovitz M, Westin SN, Nick AM, Schmeler KM, Ramirez PT. Successful incorporation of robotic surgery into gynecologic oncology fellowship training. Gynecol Oncol 131(3):730-3, 2013. e-Pub 2013. PMID: 24055616.
173. Clark LH, Soliman PT, Odetto D, Munsell MF, Schmeler KM, Fleming N, Westin SN, Nick AM, Ramirez PT. Incidence of trocar site herniation following robotic gynecologic surgery. Gynecol Oncol 131(2):400-3, 2013. e-Pub 2013. PMID: 23988416.
174. Huang M, Djordjevic B, Yates MS, Urbauer D, Sun C, Burzawa J, Daniels M, Westin SN, Broaddus R, Lu K. Molecular pathogenesis of endometrial cancers in patients with Lynch syndrome. Cancer 119(16):3027-33, 2013. e-Pub 2013. PMID: 23760948.
175. Urh A, Soliman PT, Schmeler KM, Westin S, Frumovitz M, Nick AM, Fellman B, Urbauer DL, Ramirez PT. Postoperative outcomes after continent versus incontinent urinary diversion at the time of pelvic exenteration for gynecologic malignancies. Gynecol Oncol 129(3):580-5, 2013. e-Pub 2013. PMID: 23480870.
176. Djordjevic B, Westin S, Broaddus RR. Application of Immunohistochemistry and Molecular Diagnostics to Clinically Relevant Problems in Endometrial Cancer Bojana Djordjevic, Shannon Westin, Russell R. Broaddus. Surg Pathol Clin 5(4):859-878, 2012. e-Pub 2012. PMID: 23687522.
177. Liang H, Cheung LW, Li J, Ju Z, Yu S, Stemke-Hale K, Dogruluk T, Lu Y, Liu X, Gu C, Guo W, Scherer SE, Carter H, Westin SN, Dyer MD, Verhaak RG, Zhang F, Karchin R, Liu CG, Lu KH, Broaddus RR, Scott KL, Hennessy BT, Mills GB. Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res 22(11):2120-9, 2012. e-Pub 2012. PMID: 23028188.
178. Iglesias DA, Westin SN, Rallapalli V, Huang M, Fellman B, Urbauer D, Frumovitz M, Ramirez PT, Soliman PT. The effect of body mass index on surgical outcomes and survival following pelvic exenteration. Gynecol Oncol 125(2):336-42, 2012. e-Pub 2012. PMID: 22261299.
179. Berger JL, Westin SN, Fellman B, Rallapali V, Frumovitz M, Ramirez PT, Sood AK, Soliman PT. Modified vertical rectus abdominis myocutaneous flap vaginal reconstruction: an analysis of surgical outcomes. Gynecol Oncol 125(1):252-5, 2012. e-Pub 2012. PMID: 22166844.
180. Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, Luthra R, Lee JJ, Lu KH, Kurzrock R. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 30(8):777-82, 2012. e-Pub 2012. PMID: 22271473.
181. Brown AJ, Westin SN, Broaddus RR, Schmeler K. Progestin intrauterine device in an adolescent with grade 2 endometrial cancer. Obstet Gynecol 119(2 Pt 2):423-426, 2012. e-Pub 2012. PMID: 22270425.
182. Soliman PT, Frumovitz M, Sun CC, Dos Reis R, Schmeler KM, Nick AM, Westin SN, Brown J, Levenback CF, Ramirez PT. Radical hysterectomy: a comparison of surgical approaches after adoption of robotic surgery in gynecologic oncology. Gynecol Oncol 123(2):333-6, 2011. e-Pub 2011. PMID: 21872911.
183. Westin SN, Sun CC, Lu KH, Schmeler KM, Soliman PT, Lacour RA, Johnson KG, Daniels MS, Arun BK, Peterson SK, Bodurka DC. Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma. Cancer 117(12):2659-67, 2011. e-Pub 2011. PMID: 21656744.
184. Lacour RA, Westin SN, Meyer LA, Wingo SN, Schorge JO, Brooks R, Mutch D, Molina A, Sutphen R, Barnes M, Elder J, Teoh D, Powell CB, Choubey V, Blank S, Macdonald HR, Brady MF, Urbauer DL, Bodurka D, Gershenson DM, Lu KH. Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations. Gynecol Oncol 121(2):358-63, 2011. e-Pub 2011. PMID: 21276604.
185. Cantrell LA, Westin SN, Van Le L. The use of recombinant erythropoietin for the treatment of chemotherapy-induced anemia in patients with ovarian cancer does not affect progression-free or overall survival. Cancer 117(6):1220-6, 2011. e-Pub 2011. PMID: 21381011.
186. Kincey J, Westin SN, Zhao B, Curtis MG, Ramondetta L. Surgical removal of a gigantic abdominal mass: a multidisciplinary approach. Obstet Gynecol 117(2 Pt 2):508-512, 2011. e-Pub 2011. PMID: 21252807.
187. Westin SN, Broaddus RR, Deng L, McCampbell A, Lu KH, Lacour RA, Milam MR, Urbauer DL, Mueller P, Pickar JH, Loose DS. Molecular clustering of endometrial carcinoma based on estrogen-induced gene expression. Cancer Biol Ther 8(22):2126-35, 2009. e-Pub 2009. PMID: 19755863.
188. Litton JK, Westin SN, Ready K, Sun CC, Peterson SK, Meric-Bernstam F, Gonzalez-Angulo AM, Bodurka DC, Lu KH, Hortobagyi GN, Arun BK. Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation. Cancer 115(8):1598-604, 2009. e-Pub 2009. PMID: 19280625.
189. Zhang Q, Shen Q, Celestino J, Milam MR, Westin SN, Lacour RA, Meyer LA, Shipley GL, Davies PJ, Deng L, McCampbell AS, Broaddus RR, Lu KH. Enhanced estrogen-induced proliferation in obese rat endometrium. Am J Obstet Gynecol 200(2):186.e1-8, 2009. e-Pub 2009. PMID: 19185100.
190. Westin SN, Lacour RA, Urbauer DL, Luthra R, Bodurka DC, Lu KH, Broaddus RR. Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome. J Clin Oncol 26(36):5965-71, 2008. e-Pub 2008. PMID: 19001318.
191. Lacour RA, Daniels MS, Westin SN, Meyer LA, Burke CC, Burns KA, Kurian S, Webb NF, Pustilnik TB, Lu KH. What women with ovarian cancer think and know about genetic testing. Gynecol Oncol 111(1):132-6, 2008. e-Pub 2008. PMID: 18684498.
192. Westin SN, Bustillos D, Gano JB, Fields MM, Coker AL, Sun CC, Ramondetta LM. Social factors affecting treatment of cervical cancer: ethical issues and policy implications. Obstet Gynecol 111(3):747-51, 2008. e-Pub 2008. PMID: 18310380.
193. Milam MR, Gu J, Yang H, Celestino J, Wu W, Horwitz IB, Lacour RA, Westin SN, Gershenson DM, Wu X, Lu KH. STK15 F31I polymorphism is associated with increased uterine cancer risk: a pilot study. Gynecol Oncol 107(1):71-4, 2007. e-Pub 2007. PMID: 17599395.
194. Westin SN, Skinner EN, Jonsson Funk M, Gehrig PM, Van Le L. Incidence of symptomatic deep venous thrombosis with epoetin alfa or darbepoetin alfa treatment of anemia in patients with ovarian or primary peritoneal cancer. Gynecol Oncol 105(2):414-7, 2007. e-Pub 2007. PMID: 17250880.

Review Articles

1. Willman, G, Podder, V, Westin, SN, Corr, BR, Coleman, R, Pothuri, B, Moore, KM, Slomovitz, BM. Homologous recombination deficiency in endometrial cancer. International Journal of Gynecological Cancer 36(2), 2026. e-Pub 2026. PMID: 41483491.
2. Adjei, N, Bowen, MB, Wilke, RN, Yates, MS, Westin, SN. Uterine-Conserving Treatment Options for Atypical Endometrial Hyperplasia and Early Endometrial Cancer. Current oncology reports 26(11):1367-1379, 2024. e-Pub 2024. PMID: 39361076.
3. How, JA, Jazaeri, AA, Westin, SN, Lawson, BC, Klopp, AH, Soliman, PT, Lu, KH. Translating biological insights into improved management of endometrial cancer. Nature Reviews Clinical Oncology 21(11):781-800, 2024. e-Pub 2024. PMID: 39198622.
4. Creutzberg, C, Jae, WK, Eminowicz, G, Allanson, ER, Eberst, L, Kim, SI, Nout, RA, Park, JY, Lorusso, D, Mileshkin, L, Ottevanger, PB, Brand, A, Mezzanzanica, D, Oza, A, Gebski, V, Pothuri, B, Batley, T, Gordon, C, Mitra, T, White, H, Howitt, BE, Matias-Guiu, X, Ray-Coquard, I, Gaffney, D, Small, W, Miller, A, Concin, N, Powell, MA, Stuart, GC, Bookman, M, Barretina-Ginesta, P, Bennett, K, Berek, JS, Berger, R, Bjørge, L, Boere, IA, Brennan, DJ, Bruchim, I, Chang, TC, Chávez-Blanco, A, Chen, X, Colombo, N, Crosbie, EJ, Denys, H, Duska, L, Fruehauf, F, Gomez-Garcia, E, Van Gorp, T, Liu, J, Westin, SN. Clinical research in endometrial cancer. The lancet oncology 25(9):e420-e431, 2024. e-Pub 2024. PMID: 39214113.
5. Fleming, N, Wolfe, CA, Keating, MF, Sans, M, Rangel, KM, Sunny, C, Westin, SN, Jazaeri, AA, Soliman, PT, Taylor, JS, Hillman, RT, How, JA, Lawson, BC, Sood, AK, Eberlin, LS. Feasibility of using the handheld MasSpec pen technology for intraoperative identification of ovarian cancer during tumor reductive surgery. Journal of Clinical Oncology 42:5573, 2024. e-Pub 2024.
6. Leo J, Dondossola E, Basham KJ, Wilson NR, Alhalabi O, Gao J, Kurnit KC, White MG, McQuade JL, Westin SN, Wellberg EA, Frigo DE. Stranger Things: New Roles and Opportunities for Androgen Receptor in Oncology Beyond Prostate Cancer. Endocrinology 164(6), 2023. e-Pub 2023. PMID: 37154098.
7. Avila M, Grinsfelder MO, Pham M, Westin SN. Targeting the PI3K Pathway in Gynecologic Malignancies. Curr Oncol Rep 24(12):1669-1676, 2022. e-Pub 2022. PMID: 36401704.
8. Ngoi NYL, Westin SN, Yap TA. Targeting the DNA damage response beyond poly(ADP-ribose) polymerase inhibitors: novel agents and rational combinations. Curr Opin Oncol 34(5):559-569, 2022. e-Pub 2022. PMID: 35787597.
9. Makker V, MacKay H, Ray-Coquard I, Levine DA, Westin SN, Aoki D, Oaknin A. Endometrial cancer. Nat Rev Dis Primers 7(1):88, 2021. e-Pub 2021. PMID: 34887451.
10. Pham MM, Hinchcliff E, Avila M, Westin SN. The Clinical Challenges, Trials, and Errors of Combatting Poly(ADP-Ribose) Polymerase Inhibitors Resistance. Cancer J 27(6):491-500, 2021. e-Pub 2021. PMID: 34904812.
11. Alvarez Secord A, O'Malley DM, Sood AK, Westin SN, Liu JF. Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review. Gynecol Oncol 162(2):482-495, 2021. e-Pub 2021. PMID: 34090705.
12. Hinchcliff E, Chelariu-Raicu A, Westin SN. Current and future landscape of poly (ADP-ribose) polymerase inhibition resistance. Curr Opin Obstet Gynecol 33(1):19-25, 2021. e-Pub 2021. PMID: 33315700.
13. Baxter E, Brennan DJ, McAlpine JN, Mueller JJ, Amant F, van Gent MDJM, Huntsman DG, Coleman RL, Westin SN, Yates MS, Krakstad C, Quinn MA, Janda M, Obermair A. Improving response to progestin treatment of low-grade endometrial cancer. Int J Gynecol Cancer 30(11):1811-1823, 2020. e-Pub 2020. PMID: 32381512.
14. Onstad M, Coleman RL, Westin SN. Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer. Drugs 80(15):1525-1535, 2020. e-Pub 2020. PMID: 32852746.
15. Kurnit KC, Avila M, Hinchcliff EM, Coleman RL, Westin SN. PARP inhibition in the ovarian cancer patient: Current approvals and future directions. Pharmacol Ther 213:107588, 2020. e-Pub 2020. PMID: 32450190.
16. Arend R, Westin SN, Coleman RL. Decision analysis for secondline maintenance treatment of platinum sensitive recurrent ovarian cancer: a review. Int J Gynecol Cancer 30(5):684-694, 2020. e-Pub 2020. PMID: 32079709.
17. Buechel M, Herzog TJ, Westin SN, Coleman RL, Monk BJ, Moore KN. Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option. Ann Oncol 30(5):721-732, 2019. e-Pub 2019. PMID: 30887020.
18. Labrie M, Fang Y, Kendsersky ND, Li J, Liang H, Westin SN, Mitri Z, Mills GB. Using Reverse Phase Protein Array (RPPA) to Identify and Target Adaptive Resistance. Adv Exp Med Biol 1188:251-266, 2019. e-Pub 2019. PMID: 31820393.
19. Bruinooge SS, Pickard TA, Vogel W, Hanley A, Schenkel C, Garrett-Mayer E, Tetzlaff E, Rosenzweig M, Hylton H, Westin SN, Smith N, Lynch C, Kosty MP, Williams SF. Understanding the role of advanced practice providers in oncology in the United States. JAAPA 31(12):1-12, 2018. e-Pub 2018. PMID: 30489397.
20. Dal Molin GZ, Westin SN, Coleman RL. Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease. Future Oncol 14(30):3101-3110, 2018. e-Pub 2018. PMID: 30105925.
21. Kurnit KC, Coleman RL, Westin SN. Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer. Curr Treat Options Oncol 19(12):1, 2018. e-Pub 2018. PMID: 30535808.
22. Jazaeri A, Coleman RL, Sood AK, Frumovitz MM, Soliman PT, Shafer A, Cutrera JJ, Klinger M, Sharafi SE, Johnson CAL, Villanueva VF, Hinchcliff EM, Dickens A, Cain KE, Anderson JE, Lu KH, Westin SN. A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice. Gynecol Oncol 151(2):374-380, 2018. e-Pub 2018. PMID: 30213435.
23. Bruinooge SS, Pickard TA, Vogel W, Hanley A, Schenkel C, Garrett-Mayer E, Tetzlaff E, Rosenzweig M, Hylton H, Westin SN, Smith N, Lynch C, Kosty MP, Williams SF. Understanding the Role of Advanced Practice Providers in Oncology in the United States. J Adv Pract Oncol 9(6):585-598, 2018. e-Pub 2018. PMID: 31186981.
24. Colombo I, Kurnit KC, Westin SN, Oza AM. Moving From Mutation to Actionability. Am Soc Clin Oncol Educ Book 38:495-503, 2018. e-Pub 2018. PMID: 30231353.
25. Corzo C, Barrientos Santillan N, Westin SN, Ramirez PT. Updates on Conservative Management of Endometrial Cancer. J Minim Invasive Gynecol 25(2):308-313, 2018. e-Pub 2018. PMID: 28782618.
26. Previs RA, Sood AK, Mills GB, Westin SN. The rise of genomic profiling in ovarian cancer. Expert Rev Mol Diagn 16(12):1337-1351, 2016. e-Pub 2016. PMID: 27828713.
27. Liu J, Westin SN. Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know. Gynecol Oncol 141(1):65-71, 2016. e-Pub 2016. PMID: 27016231.
28. Darin MC, Gomez-Hidalgo NR, Westin SN, Soliman PT, Escobar PF, Frumovitz M, Ramirez PT. Role of Indocyanine Green in Sentinel Node Mapping in Gynecologic Cancer: Is Fluorescence Imaging the New Standard?. J Minim Invasive Gynecol 23(2):186-93, 2016. e-Pub 2016. PMID: 26518716.
29. Klempner SJ, Myers AP, Mills GB, Westin SN. Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer. Expert Opin Pharmacother 14(16):2171-82, 2013. e-Pub 2013. PMID: 23937415.
30. Westin SN, Herzog TJ, Coleman RL. Investigational agents in development for the treatment of ovarian cancer. Invest New Drugs 31(1):213-29, 2013. e-Pub 2013. PMID: 22661305.
31. Covert WM, Westin SN, Soliman PT, Langley GD. The role of mucoregulatory agents after continence-preserving urinary diversion surgery. Am J Health Syst Pharm 69(6):483-6, 2012. e-Pub 2012. PMID: 22382478.
32. Westin SN, Broaddus RR. Personalized therapy in endometrial cancer: challenges and opportunities. Cancer Biol Ther 13(1):1-13, 2012. e-Pub 2012. PMID: 22198566.
33. Tierney B, Westin SN, Schlumbrecht MP, Ramirez PT. Early cervical neoplasia: advances in screening and treatment modalities. Clin Adv Hematol Oncol 8(8):547-55, 2010. e-Pub 2010. PMID: 20966891.
34. Meyer LA, Westin SN, Lu KH, Milam MR. Genetic polymorphisms and endometrial cancer risk. Expert Rev Anticancer Ther 8(7):1159-67, 2008. e-Pub 2008. PMID: 18588460.

Professional Educational Materials

1. Holman L, Fu S, Westin SN. (Contributor, Cervical, Endometrial & Ovarian Cancer). Handbook of Targeted Cancer Therapy. Wolters Kluwer, 2022.
2. Holman L, Fu S, Westin SN. Handbook of Targeted Cancer Therapy 2nd Edition 2019. Wolters Kluwer, 2019.
3. Holman L, Fu S, Westin SN. Handbook of Targeted Cancer Therapy. Wolters Kluwer, 2014.

Other Articles

1. Dai, Y, Knisely, A, Yano, M, Dang, M, Hinchcliff, EM, Lee, S, Welp, A, Chelvanambi, M, Lastrapes, M, Liu, H, Yuan, Z, Wang, C, Nie, H, Jean, S, Montaner, LJ, Hou, J, Patel, A, Patel, S, Fellman, B, Yuan, Y, Sun, B, Pandurengan, RK, Cuentas, EP, Celestino, J, Liu, Y, Liu, J, Hillman, RT, Westin, SN, Sood, AK, Soliman, PT, Shafer, A, Meyer, LA, Gershenson, DM, Vining, D, Ganeshan, DM, Lu, KH, Wargo, J, Peng, W, Zhang, R, Wang, L, Jazaeri, AA Author Correction. Nature 645(8082):E10, 2025. PMID: 40913056.
2. Hutchcraft, ML, Rios-Doria, E, Sia, TY, Teplinsky, E, Westin, SN, Nelson, G #HashtagThis – Everything you need to know about launching your gynecologic oncology social media research career. Gynecologic Oncology Reports 54, 2024.
3. Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi HA, Hwu P, Oliva ICG, Davies MA, Patel SP, Zou J, Futreal A, Diab A, Wang L, Nurieva R Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun 15(1):5621, 2024. PMID: 38965214.
4. Bogani G, Monk BJ, Powell MA, Westin SN, Slomovitz B, Moore KN, Eskander RN, Raspagliesi F, Barretina-Ginesta MP, Colombo N, Mirza MR Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer. Ann Oncol 35(5):414-428, 2024. PMID: 38431043.
5. Vellano CP, White MG, Andrews MC, Chelvanambi M, Witt RG, Daniele JR, Titus M, McQuade JL, Conforti F, Burton EM, Lastrapes MJ, Ologun G, Cogdill AP, Morad G, Prieto P, Lazar AJ, Chu Y, Han G, Khan MAW, Helmink B, Davies MA, Amaria RN, Kovacs JJ, Woodman SE, Patel S, Hwu P, Peoples M, Lee JE, Cooper ZA, Zhu H, Gao G, Banerjee H, Lau M, Gershenwald JE, Lucci A, Keung EZ, Ross MI, Pala L, Pagan E, Segura RL, Liu Q, Borthwick MS, Lau E, Yates MS, Westin SN, Wani K, Tetzlaff MT, Haydu LE, Mahendra M, Ma X, Logothetis C, Kulstad Z, Johnson S, Hudgens CW, Feng N, Federico L, Long GV, Futreal PA, Arur S, Tawbi HA, Moran AE, Wang L, Heffernan TP, Marszalek JR, Wargo JA Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature 613(7945):E3, 2023. PMID: 36627494.
6. Sun, H, Cao, S, Mashl, RJ, Mo, CK, Zaccaria, S, Wendl, MC, Davies, S, Bailey, MH, Primeau, T, Hoog, J, Mudd, JL, Dean, DA, Patidar, R, Chen, L, Wyczalkowski, MA, Jayasinghe, R, Rodrigues, FM, Terekhanova, NV, Li, Y, Lim, KH, Wang-Gillam, A, Van Tine, BA, Ma, C, Aft, R, Fuh, KC, Schwarz, JK, Roth, JA, Tapia, C, Yang, F, Akcakanat, A, Chen, H, Dai, B, Gibbons, DL, Ha, MJ, Jensen, VB, Kim, M, Kopetz, S, Menter, DG, Meraz, I, Sorokin, A, Wang, J, Westin, SN, Xi, Y, Yap, TA, Yennu Nanda, VG, Zhang, X, Zheng, X, Davies, MA, Fang, B, Meric-Bernstam, F Author Correction. Nature communications 13(1), 2022. PMID: 34996889.
7. Woo, XY, Giordano, J, Srivastava, A, Zhao, ZM, Lloyd, M, de Bruijn, R, Suh, YS, Patidar, R, Chen, L, Scherer, S, Bailey, M, Yang, CH, Cortes-Sanchez, E, Xi, Y, Wang, J, Wickramasinghe, JM, Kossenkov, AV, Rebecca, VW, Sun, H, Mashl, RJ, Davies, S, Jeon, R, Frech, C, Randjelovic, J, Rosains, J, Galimi, F, Bertotti, A, Lafferty, A, O’Farrell, AC, Modave, E, Fang, B, Roth, JA, Meric-Bernstam, F, Davies, MA, Zheng, X, Zhang, X, Akcakanat, A, Yap, TA, Ha, MJ, Chen, H, Kopetz, S, Menter, DG, Westin, SN, Kim, M, Dai, B, Gibbons, DL, Tapia, C, Jensen, VB, Yennu Nanda, VG, Mælandsmo, GM Author Correction. Nature Genetics 53(5):761, 2021. PMID: 33608693.
8. Westin SN The obstetric forceps: shrouded in mystery. Obstet Gynecol Surv 61(6):357-8, 2006. PMID: 16719940.
9. Neville S Ignaz Semmelweis. Primary Care Update Obstetrics/Gynecology 20:1-2, 2003.

Editorials

1. Hinchcliff E, Westin SN, Herzog TJ. State of the science: Contemporary front-line treatment of advanced ovarian cancer. Gynecol Oncol 166(1):18-24, 2022. PMID: 35589433.
2. Hinchcliff EM, Westin SN. Next generation sequencing for gynecologic malignancy: Promise and potential pitfalls. Gynecol Oncol 163(2):217-219, 2021. PMID: 34756289.
3. Stewart KI, Yates MS, Westin SN. Pushing the envelope: expanding fertility sparing treatment of endometrial cancer. J Gynecol Oncol 31(5):e82, 2020. PMID: 32808503.
4. Hinchcliff EM, Meyer LA, Westin SN. Has dose-dense chemotherapy met an ICONic end?. Lancet Oncol 21(7):869-870, 2020. PMID: 32615101.
5. Kurnit KC, Westin SN. Slow and steady wins the race: precision medicine for low risk endometrial cancer. Int J Gynecol Cancer 30(6):724-725, 2020. PMID: 32376741.
6. Westin SN, Coleman RL. Individualized Medicine in Ovarian Cancer: Are We There Yet?. Gynecol Oncol 144(2):229-231, 2017. PMID: 28089051.
7. Westin SN, Mills GB, Myers AP. Repurposing the Pap smear: one step closer to gynecologic cancer screening. Sci Transl Med 5(167):167ps1, 2013. PMID: 23303602.

Abstracts

1. Fleming ND, Wolfe CA, Keating M, Sans M, Rangel KM, Sunny C, Westin SN, Jazaeri AA, Soliman PT, Taylor JS, Hillman RT, How JA, Lawson B, Sood AK, Eberlin LS. Feasibility of using the handheld MasSpec pen technology for intraoperative identification of ovarian cancer during tumor reductive surgery, 2024. e-Pub 2024.
2. Nieuwenhuysen EV, Baurain J, Chon HS, Pepin JT, Sundborg MJ, Gold MA, Kim B, Blank SV, Liu J, McCollum M, Mori M, Jonuškienė G, Moore KN, Novák Z, Ramos P, de Padua CAJ, Gil-Martin M, Kowgier M, del Rosario PM, Westin SN. Durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer (EC) in DUO-E: Results by BRCA1/BRCA2 mutation (BRCAm) status, 2024. e-Pub 2024.
3. Knisely A, Rafei H, Basar R, Banerjee PP, Metwalli Z, Lito K, Fellman BM, Yuan Y, Wolff RA, Morelli MP, Meyer LA, Wang XS, Westin SN, Meric-Bernstam F, Shpall EJ, Lu KH, Rezvani K, Jazaeri AA. Phase I/II study of TROP2 CAR engineered IL15-transduced cord blood-derived NK cells delivered intraperitoneally for the management of platinum resistant ovarian cancer, mesonephric-like adenocarcinoma, and pancreatic cancer, 2024. e-Pub 2024.
4. Constanzo JD, Prescott LS, Westin SN, Salani R, Pan EY, Avila-Wallace M, Chon HS, Rosenthal KM, Hoskins ER, Chapman-Davis E. Overcoming barriers in equitable care delivery for women with gynecologic cancers: Outcomes and analysis from an educational program on health equity. Journal Clinical Oncology, 2024. e-Pub 2024.
5. Eyada M, Michael V, Fellman BM, Patel S, Soliman PT, How JA, Jazaeri AA, Fleming ND, Sood AK, Westin SN, Sims TT. Oral cyclophosphamide plus bevacizumab in recurrent ovarian, fallopian tube and primary peritoneal cancer. Journal of Clinical Oncology: ASCO Publications, 2024. e-Pub 2024.
6. Eyada M, Fellman BM, Patel S, Michael V, Soliman PT, Sims TT, How JA, Jazaeri AA, Fleming ND, Ramondetta LM, Westin SN. Gemcitabine plus cisplatin in recurrent ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology: ASCO Publications, 2024. e-Pub 2024.
7. Westin SN, Moore KN, Chon HS, Lee J, Pepin JT, Sundborg M, La Garza JD, Nishio S, Wang K, Mcintyre K, Tillmanns TD, Mejia FC, De Melo AC, Klasa-Mazurkewicz D, Papadimitriou C, Gil-Martin M, Brasiuniene B, Donnelly C, Liu X, Nieuwenhuysen EV. 619 Durvalumab plus carboplatin/paclitaxel followed by durvalumab ± olaparib as a first-line treatment for newly diagnosed advanced or recurrent endometrial cancer: results from the phase III DUO-E/GOG-3041/ENGOT-EN10 Trial. International Journal of Gynecologic Cancer 2024, 2023. e-Pub 2023.
8. Adjei N, Coleman R, Fellman B, Tran S, Yuan Y, Ozmen TY, Ozmen F, Sood A, Soliman P, Wright AA, Horowitz N, Campos S, Konstantinopoulos P, Gershenson D, Lu K, Patel A, Ruben C, Rabbitt A, Ottesen L, Ghiorghiu D, Godin R, Liu J, Mills G, Westin S. Effort: clinical and molecular features associated with clinical benefit from adavosertib with or without olaparib in recurrent ovarian cancer following progression on PARP inhibition (NCT03579316). International Journal of Gynecologic Cancer, 2023. e-Pub 2023.
9. Fleming N, Keating M, Wolfe C, Sans M, Rangel K, Sey E, Westin S, Jazaeri A, Soliman P, Taylor J, Hillman T, Lawson B, Liu J, Sood A, Eberlin L. Intraoperative identification of ovarian cancer during tumor reductive surgery using the hand-held masspec pen technology. International Journal of Gynecologic Cancers, 2023. e-Pub 2023.
10. Pepin JT, Chon HS, Sundborg MJ, Gold MA, Kim B, Blank SV, Liu J, McCollum M, Mori M, Moore KN, Diaz JR, de Padua CAJ, Martínez-García J, Papadimitriou C, an KG, Póka R, Kowgier M, Oscroft E, Nieuwenhuysen EV, Westin SN. Safety and tolerability of durvalumab + carboplatin/paclitaxel followed by durvalumab ± olaparib in patients with newly diagnosed advanced or recurrent endometrial cancer (EC) in the DUO-E/GOG-3041/ENGOT-EN10 trial. Journal of Clinical Oncology, 2023. e-Pub 2023.
11. Pham M, Scalise CB, Kalashnikova E, Dutta P, Chen X, Narcisse S, Rangel K, Urbauer D, Elnaggar A, Westin <, Jazaeri A, Lu K, Soliman P. EP159/#1534 Leveraging personalized circulating tumor DNA monitoring to predict treatment response and recurrence in high-risk endometrial cancer. International Journal of Gynecologic Cancer, 2023. e-Pub 2023.
12. Westin SN, Coleman RL, Fellman BM, Yuan Y, Sood AK, Soliman PT, Wright AA, Horowitz NS, Campos SM, Konstantinopoulos PA, Levenback CF, Gershenson DM, Lu KH, Bayer V, Tukdi S, Rabbit A, Ottesen L, Godin R, Mills GB, Liu JF. EFFORT: EFFicacy Of adavosertib in parp ResisTance: A randomized two-arm non-comparative phase II study of adavosertib with or without olaparib in women with PARP-resistant ovarian cancer. ASCO Virtual Annual Meeting, Journal of Clinical Oncology 39(15):5505, 2021. e-Pub 2021.
13. Westin SN, Fu S, Tsimberidou AM, Piha-Paul SA, Akhmedzhanov F, Yilmaz B, McQuinn L, Brink AL, Gong J, Leung CH, Lin HY, Hong DS, Pant S, Jazaeri AA, Gershenson DM, Sood AK, Coleman RL, Shah JJ, Meric-Bernstam F, Naing A. solid tumors: Results of an open label, single-center, multi-arm phase 1b study. ASCO Virtual Annual Meeting, Journal of Clinical Oncology 39(15):5565, 2021. e-Pub 2021.
14. Sims TT, Sood AK, Westin SN, Fellman B, Unke J, Rangel K, Hilton T, Fleming ND. Correlation of HRD status with clinical and survival outcomes in patients with advanced-stage ovarian cancer. ASCO Virtual Annual Meeting, Journal of Clinical Oncology 39(15):5568, 2021. e-Pub 2021.
15. Morris V, Jazaeri AA, Westin SN, Pettaway C, George S, Huey R, Onstad M, Tu SM, Wang J, Shafer A, Johnson B, Xiao L, Vining D, Guo M, Yuan Y, Frumovitz MM. Phase II trial of MEDI0457 and durvalumab for patients with recurrent/metastatic HPV-associated cancers 39(15):2595, 2021. e-Pub 2021.
16. Hinchcliff E, Westin SN, Bayer V, Peng W, Wang L, Fellman B, Yuan Y, Sood AK, Lu KH, Jazaeri AA. Phase I/II study of AVB-S6-500 in Combination with Durvalumab (MEDI4736) in Patients with Platinum-Resistant, Recurrent Epithelial Ovarian Cancer, 2021. e-Pub 2021.
17. Westin SN, Fellman B, Yuan Y, Soliman PT, Fleming ND, Cobb L, Shafer A, Taylor J, Jazaeri AA, Frumovitz MM, Ramirez PT, Meyer LA, Alvarado T, Hull S, KH, Mills GB, Coleman RL. ENPAC: Phase II trial with safety lead in of enzalutamide in combination with paclitaxel and carboplatin for advanced or recurrent endometrioid endometrial adenocarcinoma, 2021. e-Pub 2021.
18. Hinchcliff E, Patel A, Fellman B, Yuan Y, Westin SN, Sood AK, Soliman PT, Frumovitz MM, Shafer A, Meyer LA, Fleming ND, Vikram R, Bathala T, Vining D, Ganeshan D, Hwu P, Lu KH, Amir Jazaeri AA. Randomized Phase II trial of Durvalumab (anti-PDL1) and Tremelimumab (anti-CTLA4) in Combination versus Sequential administration in recurrent platinum-resistant non-clear cell ovarian cancer, 2021. e-Pub 2021.
19. Wu Y, Hu W, Jennings NB, Sun Y, Westin SN, Sood AK. Betting on BET inhibitors: Targeting the macrophage axis to improve anti-angiogenesis therapy in ovarian cancer, 2021. e-Pub 2021.
20. Handley KF, Sood AK, Zibetti Dal Molin G, Westin SN, Meyer LA, Fellman B, Soliman PT, Fleming ND. Frailty Repels the Knife: The Impact of Frailty Index on Surgical Intervention and Outcomes, 2021. e-Pub 2021.
21. How J, Patel S, Fellman B, Lu KH, Ramondetta L, Westin SN, Fleming ND, Soliman PT, Jazaeri AA. The use of pembrolizumab and lenvatinib combination therapy in endometrial cancer: an examination of toxicity and treatment efficacy in clinical practice, 2021. e-Pub 2021.
22. Westin SN, Moore K, Van Niewwenhuysen E, Oza A, Mileshkin L, Okamoto A, Bodnar L Papadimitriou C, Barker L, Meyer K, Suzuki A, Rhee J, Vergote K. DUO-E GOG-3041/ENGOT-EN10: A randomized phase III trial of first-line carboplatin and paclitaxel in combination with durvalumab, followed by maintenance durvalumab with or without olaparib in patients with newly diagnosed advanced or recurrent endometrial cancer, 2021. e-Pub 2021.
23. Abo-Zahrah R, Karp DD, Adat A, Yap TA, Fu S, Rodon Ahnert J, Piha-Paul SA, Tsimberidou AM, Naing A, Subbiah V, Dumbrava EI, Overman MJ, Patel SP, Amaria RN, Westin SN, Meric-Bernstam F, Janku F. Patients with advanced solid cancers treated with ERK inhibitors exhibit pseudo-progression in lymphatic nodes 39(15):3138, 2021. e-Pub 2021.
24. Handley KF, Sims TT, Glassman D, Fleming ND, Lee S, Yao H, Yao J, Liu J, Bast RC, Westin SN, Celestino J, Rangel K, Conrads TP, Maxwell GL, Ram PT, Sood AK. If Looks Could Kill: Morphologic Subtypes of High-Grade Serous Ovarian Cancer, 2021. e-Pub 2021.
25. Lee S, Zhao L, Little LD, Westin SN, Jazaeri AA, Fleming ND, Hajek RA, Zhang J, Futreal PA, Sood AK. Distinct T cell receptor diversity and integrative analyses of clinically defined high-grade serous ovarian cancer, 2021. e-Pub 2021.
26. Fu S, Yao S, Yuan Y, Previs RA, Elias AD, Carvajal R, George TJ, Yamamura Y, Westin SN, Xing X, Dumbrava EI, Karp D, Piha-Paul S, Tsimberidou A, Rodon Ahnert J, Takebe N, Kunos C, Lu K, Keyomarsi K, Meric-Bernstam F. Phase II trial of the Wee1 inhibitor adavosertib in advanced refractory solid tumors with CCNE1 amplification 81(13):Abstract nr 974, 2021. e-Pub 2021.
27. Lee S, Zhao L, Celestino J, Hajek RA, Morgan MB, Kim MS, Westin SN, Jazaeri AA, Fleming ND, Liu J, Zhang J, Futreal PA, Sood AK. NF1 copy number alterations in clinically-defined subsets of high-grade serous ovarian cancers 81(13):Abstract nr 2200, 2021. e-Pub 2021.
28. Mulder IA, Fleming ND, Sun CC, Fellman B, Ulin L, Ozer M, Coleman RL, Ramirez PT, Rangel KM, Soliman PT, Nick AM, Lu KH, Sood AK, Westin SN. Impact of a Laparoscopic Triage Program for Advanced Ovarian Cancer on Surgical Outcomes, disease-free Survival, and Overall Survival. IGCS Virtual Meeting, International Journal Gynecologic Cancer 30(3):A165, 2020. e-Pub 2020.
29. Meyer LA, Molina E, Schneider AK, Harrison RF, Westin SN, Coleman RL, Lowenstein LM, Volk R, Sun CC. Patient preferences for side effects and decision-making factors associated with maintenance therapy for ovarian cancer. SGO Virtual Annual Meeting, Gynecologic Oncology 159(1):75, 2020. e-Pub 2020.
30. Frumovitz MM, Westin SN, Yap TA, Rodon JA, Karp DD, Abonofal A, Jazaeri AA, Naing A. Phase II study of pembrolizumab for high-grade neuroendocrine tumors of the cervix and vulva. SGO Virtual Annual Meeting, Gynecologic Oncology 159(1):23, 2020. e-Pub 2020.
31. Hansen JM, Ring KL, Hu W, Dood RL, Wang Y, Baggerly K, Gallagher S, Tshiaba P, Neff C, Timms KM, Lingegowda S Mangala LS, Westin SN, Broaddus RR, Lopez-Berestein G, Lu KH, Coleman RL, Maxwell GL, Sood AK. Significance of Homologous Recombination Deficiency Score Testing in Endometrial Cancer. SGO Virtual Annual Meeting, Gynecologic Oncology 159(1):225, 2020. e-Pub 2020.
32. Moufarrij S, Sood AK, Westin SN, Meyer LA, Fellman B, Rangel K, Hilton T, Soliman PT, Shafer A, Jazaeri AA, Coleman RL, Rauh-Hain A, Lu KH, Fleming ND. Socioeconomic barriers to care in advanced ovarian cancer: Does a one-size fits all model exist when treated at a NCI-designated tertiary cancer center?. SGO Virtual Annual Meeting, Gynecologic Oncology 159(1):246-47, 2020. e-Pub 2020.
33. Sun CC, Molina E, Schneider AK, Harrison RF, Westin SN, Coleman RL, Lowenstein LM, Volk R, Meyer LA. Patient preferences for maintenance therapy vs. routine surveillance: Gain in progression-free survival and risks of adverse effects. SGO Virtual Annual Meeting, Gynecologic Oncology 159(1):75-76, 2020. e-Pub 2020.
34. Harrison R, Zhao H, Fu S, Sun CC, Westin SN, Lu KH, Giordano S, Meyer LA. Is an endometrial cancer diagnosis a “teachable moment” leading to weight loss among obese women? A case control study. SGO Virtual Annual Meeting, Gynecologic Oncology 159(1):225-6, 2020. e-Pub 2020.
35. Fleming ND, Dal Molin G, Fellman B, Cain K, Taylor J, Schmeler K, Coleman RL, Afshar-Kharghan V, Westin SN, Sood AK. Lack of utility of the Khorana score for predicting VTE in advanced ovarian cancer. SGO Virtual Annual Meeting, Gynecologic Oncology 159(1):111, 2020. e-Pub 2020.
36. Westin SN, Lee, S, Zhao L, Yuan Y, Wu J, Hajek R, Sharafi S, Meyer LA, Fleming ND, Jazaeri AA, Coleman RL, Lu KH, Mills GB, Zhang J, Futura PA, Sood AK. Pharmacodynamic changes by durvalumab in combination with chemotherapy in women with untreated, advanced stage ovarian cancer. AACR Virtual Annual Meeting, Cancer Research 80(16):nr CT188, 2020. e-Pub 2020.
37. Lee S, Zhao L, Celestino J, Rangel KM, Hajek RA, Kim MS, Sharafi SE, Liu J, Fleming ND, Lu KH, Zhang J, Futreal PA, Mills GB, Westin SN, Sood AK, Jazaeri AA, Coleman RL. Functional proteomic aberrations post-chemotherapy with paclitaxel and carboplatin in patients with advanced ovarian cancer. AACR Virtual Annual Meeting, Cancer Research 80(16):nr 2941, 2020. e-Pub 2020.
38. Beavers RN, Fellman B, Eyada M, Klopp AH, Fleming ND, Lu KH, Soliman PT, Westin SN. Is platinum-free interval relevant in recurrent uterine serous carcinoma?. SGO Virtual Annual Meeting, Gynecologic Oncology 159(1):206-06, 2020. e-Pub 2020.
39. Turell W, Ackbarali T, Coleman RL, Westin SN, Smith JA. Results of a deep-dive survey on practice patterns of oncologists and advanced practice providers utilizing PARP inhibitors as maintenance therapy for patients with ovarian cancer. ASCO Virtual Annual Meeting, Journal of Clinical Oncology 38(15):e18044, 2020. e-Pub 2020.
40. Lee S, Zhao L, Westin SN, Bateman NW, Celestino J, Jazaeri AA, Fleming ND, Lu KH, Coleman RL, Mills GB, Zhang J, Conrads TP, Maxwell GL, Futreal PA, Sood AK. High-depth whole genome sequencing of clinically-annotated high-grade serous ovarian cancers. AACR Virtual Annual Meeting, Cancer Research 80(16):nr 2510, 2020. e-Pub 2020.
41. Westin SN, Moore KN, Van Nieuwenhuysen E, Oza A, Mileshkin L, Okamoto A, Bodnar L, Papadimitriou C, Barker L, Meyer K, Suzuki A, Rhee J, Vergote I. DUO-E/GOG-3041/ENGOT-EN10: a randomized Phase III trial of first-line carboplatin (carb) and paclitaxel (pac) in combination with durvalumab (durva), followed by maintenance durva with or without olaparib (ola), in patients (pts) with newly diagnosed (nd) advanced or recurrent endometrial cancer (EC). ASCO Virtual Annual Meeting, Journal of Clinical Oncology 38(15):TPS6108, 2020. e-Pub 2020.
42. Brown J, Miller A, Moxley K, Backes F Nagel C, Bender D, Miller D, Powell M, Westin SN Bonebrake A, Muller C, Alvarez Secord A, Crane E, Schorge J, Tew W, Sood AK, Aghajanian C. Results of a Randomized Phase II Trial of Paclitaxel and Carboplatin Versus Bleomycin, Etoposide and Cisplatin for Newly Diagnosed and Recurrent Chemonaive Stromal Ovarian Tumors. IGCS Virtual Meeting, International Journal of Gynecologic Cancer, 2020. e-Pub 2020.
43. Zibetti Dal Molin G, Westin SN, Msaouel P, Gomes LM, Dickens A, Coleman RL. Discrepancy in calculated and measured glomerular filtration rates in patients treated with PARP inhibitors. Int J Gynecol Cancer. e-Pub 2019. PMID: 31792084.
44. Labrie M, Fang Y, Kendsersky ND, Li J, Liang H, Westin SN, Mitri Z, Mills GB. Using Reverse Phase Protein Array (RPPA) to Identify and Target Adaptive Resistance. Adv Exp Med Biol 1188:251-266, 2019. e-Pub 2019. PMID: 31820393.
45. Stewart KI, Eska J, Abraham A, Chisholm G, Meyer LA, Westin SN, Fleming ND, Frumovitz MM, Aloia T, Soliman PT. Implementation of a sentinel lymph node mapping algorithm for endometrial cancer: Surgical outcomes and hospital charges. SGO Annual Meeting, Gynecologic Oncol 154(1):199-200, 2019. e-Pub 2019.
46. Meyer LA, Shi Q, Lin HK, Schneider AK, Molina E, Williams L, Savelieva K, Soliman PT, Westin SN, Wang XS, Sun CC. Symptom trajectory in women with recurrent ovarian cancer: How does symptom burden change near the end of life?. SGO Annual Meeting, Gynecologic Oncol 154(1):160, 2019. e-Pub 2019.
47. Meyer LA, Sun CC, Savelieva K, Leal VB, Crocker LC, Molina E, Westin SN, Coleman RL, Volk RJ, Lowenstein LM. Patient decision-making regarding maintenance therapy for ovarian cancer: A qualitative exploration. SGO Annual Meeting, Gynecologic Oncol 154(1):25-26, 2019. e-Pub 2019.
48. Berg HF, Ju Z, Myrvold M, Fasmer KE, Halle MK, Westin SN, Trovik J, Haldorsen IS, Mills GB, Krakstad C, Werner HM. Integrative Model for Prediction of Lymph Node Metastasis in Endometrioid Endometrial Carcinoma. European Society of Gynecologic Oncology. Athens, Greece, International Journal of Gynecologic Cancer 39(4):A109-110, 2019. e-Pub 2019.
49. Fleming ND, Westin SN, Meyer LA, Rauh-Hain A, Shafer A, Onstad M, Cobb L, Bevers M, Burzawa J, Zand B, Fellman B, Jazaeri AA, Levenback C, Coleman RL, Soliman PT, Sood AK. Correlation of surgeon radiology assessment with laparoscopic scoring in patients with advanced-stage ovarian cancer. International Journal Gynecologic Cancer 29(3):A125-26, 2019. e-Pub 2019.
50. Christopolou A, Marme F, Oaknin A, Lorusso D, Safra T, Lindahl G, Chudecka-Glaz, A, Ciuleanu T, Collins DC, Demikiran F, Lifrenko I, Van Grop T, Coleman RL, Fujiwara K, Oza AM, Westin SN, O’Malley DM, Herzog TJ, Eskander R, Wilson M, Argire S, Grechko N, McNeish IA, Monk BJ, Kristeleit RS. ATHENA (GOG-3020/ENGOT-ov45): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study of the Poly(ADP-Ribose) Polymerase (PARP) Inhibitor Rucaparib + the PD-1 Inhibitor Nivolumab Following Frontline Platinum-Based Chemotherapy in Ovarian Cancer. Poster Presentation, European Society of Gynecologic Oncology. International Journal of Gynecologic Cancer 29(4):A130-131, 2019. e-Pub 2019.
51. Hinchcliff E, Peng W, Bayer V, Haymaker C, Huang S, Sheth R, Westin SN, Lu KH, Hwu P, Jazaeri AA. Phase Ib Clinical Investigation of Intraperitoneal Ipilimumab and Nivolumab in Patients with Peritoneal Carcinomatosis Due to Gynecologic Malignancy. ASCO Annual Meeting, J Clinical Oncology 37(15), 2019. e-Pub 2019.
52. Harrison R, Cantor SB, Villanueva M, Suidan R, Sun CC, Rauh-Hain JA, Westin SN, Fleming ND, Sood AK, Lu KH, Meyer LA. Cost-effectiveness analysis of laparoscopic disease assessment in ovarian cancer. ASCO Annual Meeting, J Clinical Oncology 37(15), 2019. e-Pub 2019.
53. Previs RA, Spinosa D, Fellman B, Lorenzo AM, Mulder I, Mahmoud M, Enbaya A, Hansen J, Cobb L, Soliman PT, Coleman RL, Alvarez Secord A, Westin SN. Bevacizumab beyond progression: Impact of subsequent bevacizumab retreatment in patients with ovarian, fallopian tube, and peritoneal cancer after progression. ASCO Annual Meeting, J Clinical Oncology 37(15):5557, 2019. e-Pub 2019.
54. Westin SN, Louie-Gao, M, Badamgarav E, Bala M, Thaker PH. Risk factors for progression or death in OC pts who completed 1L platinum treatment. ASCO Annual Meeting, J Clinical Oncology 37(15), 2019. e-Pub 2019.
55. LaFargue CJ, Fleming ND, Nick AM, Chelariu-Raicu A, Fellman B, Castellano T, Ogasawara A, Hom M, Blake E, Crim AK, Westin SN, Coleman RL, Matsuo K, Hasegawa K, Moore K, Sood AK. . Diamonds in the rough: an analysis of complete pathologic responders in ovarian cancer. SGO Annual Meeting, Gynecologic Oncol 154(1):176, 2019. e-Pub 2019.
56. Harrison RF, He W, Zhao H, Sun CC, Suidan RS, Woodard TL, Rauh-Hain A, Westin SN, Giordano SH, Meyer LA. National Patterns of Care and Fertility Outcomes for Reproductive-aged Women with Endometrial Cancer or Hyperplasia with Atypia, 1999-2014. SGO Annual Meeting, Gynecologic Oncol 154(1):18-19, 2019. e-Pub 2019.
57. Dal Molin GZ, Fleming ND, Westin SN, Fellman B, Coleman RL, Afshar-Kharghan V, Sood AK. A new risk model to predict venous thromboembolism in ovarian cancer. SGO Annual Meeting, Gynecologic Oncol 154(1):208-9, 2019. e-Pub 2019.
58. Westin SN, Kristeleit RS, Coleman RL, Fuijiwara K, Oza AM, O’Malley DM, Herzog TJ, Marme F, Oaknin A, Eskander R, Lorusso D, Safra T, Korach J, Lin KK, Shih D, Caunt L, Goble S, Hume S, Maloney L, MiNeish I, Monk BJ. ATHENA (GOG-3020/ENGOT-ov45): a randomized, double-blind, placebo-controlled, Phase III study of rucaparib + nivolumab following front-line platinum-based chemotherapy in ovarian cancer. AACR Annual Meeting, Cancer Research 79(13):Abstract nr CT158, 2019. e-Pub 2019.
59. Kurnit K, Meric-Bernstam F, Hess K, Coleman RL, Bhosale P, Savelieva K, Janku F, Hong D, Naing A, Pant S, Rodon J, Yap TA, Sood AK, Soliman PT, Gershenson DM, Mills GB, Westin SN. Phase I dose escalation of olaparib (PARP inhibitor) and selumetinib (MEK Inhibitor) combination in solid tumors with Ras pathway alterations. AACR Annual Meeting, Cancer Research 79(13):Abstract nr CT020, 2019. e-Pub 2019.
60. Labrie M, Fang Y, Ju Z, Litton JK, Kim T, Lee S, Lu Y, Chen K, Soliman PT, Frumovitz MM, Meyer LA, Moulder S, Jazaeri AA, Lu KH, Sood AK, Coleman RL, Mills GB, Westin SN. Exploration of Markers of Synergistic Lethality of PARP and PI3K-Akt-mTOR Inhibitors in Women's Cancers. AACR Annual Meeting, Cancer Research 79(13):Abstract nr 2070, 2019. e-Pub 2019.
61. Kurnit KC, Previs RA, Soliman PT, Westin SN, Klopp AH, Fellman BM, Lu KH, Ramondetta LM, Fleming ND. Prognostic factors impacting survival in early stage uterine carcinosarcoma. Gynecol Oncol. e-Pub 2018. PMID: 30414738.
62. Westin SN, Nieves-Neira W, Lynam C, Salim KY, Sivia AK, Ho RT, Mills GB, Coleman RL, Janju F, Matei D. Safety and early efficacy signals for COTI-2, an orally available small molecule targeting p53, in a phase I trial of recurrent gynecologic cancer. 2018 Annual AACR Meeting, 2018. e-Pub 2018.
63. Westin SN, Litton JK, Williams R, Shepherd CJ, Brugger W, Pease EJ, Soliman PT, Frumovitz MM, Levenback C, Sood AK, Meyer LA, Moulder S, Valero V, Saleem S, Rodriguez AM, Cyriac A, Engerman L, Samuel C, Mills GB, Coleman RL. Phase I trial of olaparib (PARP inhibitor) and vistusertib (mTORC1/2 inhibitor) in recurrent endometrial, ovarian and triple negative breast cancer. ASCO Annual Meeting, Journal of Clinical Oncology 36(15):5504-05, 2018. e-Pub 2018.
64. Previs RA, Soliman PT, Westin SN, Klopp AH, Fellman B, Ramondetta LM, Fleming ND. Long-term outcomes associated with early-stage uterine carcinosarcoma: Does adjuvant therapy have a significant effect on survival?. SGO Annual Meeting, Gynecologic Oncol 149(1):194, 2018. e-Pub 2018.
65. Hansen JM, Sood AK, Coleman RL, Westin SN, Ramirez PT, Fellman B, Soliman PT, Schmeler KM, Fleming ND. Concordance of laparoscopy in predicting intraperitoneal spread and residual disease at tumor reductive surgery in advanced ovarian cancer. SGO Annual Meeting, Gynecologic Oncol 149(1):101, 2018. e-Pub 2018.
66. Stewart KI, Chasen B, Erwin W, Munsell MF, Westin SN, Dioun S, Frumovitz MM, Ramirez PT, Lu KH, Wong F, Soliman PT. The utility of preoperative PET/CT in the detection of extrauterine disease in high risk endometrial cancer: A prospective study. SGO Annual Meeting, Gynecologic Oncol 149(1):32, 2018. e-Pub 2018.
67. LaFargue CJ, Fleming ND, Fellman R, Dood RL, Lara OD, Dal Molin GZ, Westin SN, Coleman RL, Sood AK. From unresectable to cancer-free at interval tumor reductive surgery: An evaluation of complete pathologic responders. SGO Annual Meeting Gynecologic Oncol 149(1):87, 2018. e-Pub 2018.
68. Dal Molin GZ, Fleming ND, Fellman B, Dood R, Lara OD, LaFargue CJ, Coleman RL, Soliman PT, Schmeler KM, Westin SN, Sood AK. VTE in ovarian cancer during neoadjuvant chemotherapy – is it time to start prophylaxis?. SGO Annual Meeting, Gynecologic Oncol 149(1):155, 2018. e-Pub 2018.
69. Meyer LA, Sun CC, Haq S, Shi Q, Williams LA, Savelieva K, Coleman RL, Mills GB, Westin SN. Longitudinal patient-reported outcomes (PROs) for a phase 1b trial of a PARP inhibitor olaparib combined with an oral mTORC1/2 inhibitor (AZD2014) or an AKT inhibitor (AZD5363. ASCO Annual Meeting, Journal of Clinical Oncology 36(15), 2018. e-Pub 2018.
70. Hinchcliff E, Coleman RL, Lu KH, Meyer LA, Westin SN, Hwu P, Shi Q, Munsell M, Vikram R, Ganeshan D, Jazaeri AA. Randomized Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab Administered in Combination Versus Sequentially in Recurrent Platinum-Resistant Epithelial Ovarian Cancer. ASCO Annual Meeting, Journal of Clinical Oncology 36(15), 2018. e-Pub 2018.
71. Randall LM, Aydin E, Louie-Gao M, Hazard S, Westin SN. A Retrospective Analysis of Real-World Tumor BRCA (tBRCA) Testing Trends in Ovarian Cancer (OC) Before and After PARP Inhibitor Approvals. IGCS Global Meeting, International Journal of Gynecolgoic Cancer 238(2), 2018. e-Pub 2018.
72. Fleming ND, Fellman BM, Jhingran A, Soliman PT, Armbruster SD, Westin SN. A 16-year experience with early-stage uterine clear cell carcinoma: Are we over-treating?. SGO 49th Annual Meeting, 2018. e-Pub 2018.
73. Mauland KK, Ju Z, Tangen IL, Berg A, Bjorge L, Westin SN, Krakstad C, Trovik J, Mills GB, Werner HM. Proteomic profilig of endometrioid endometrial cancer reveals differential expression of hormone receptors and MAPK signaling proteins in obese versus non-obese patients. European Society of Gynecologic Oncology. International J Gyn Cancer 27(4), 2017. e-Pub 2017.
74. Suidan RS, Sun CC, Cantor SB, Mariani A, Soliman PT, Westin SN, Lu KH, Giordano SH, Meyer LA. A Cost-Utility Analysis of Sentinel Lymph Node Mapping, Selective Lymphadenectomy, and Routine Lymphadenectomy in the Management of Low-Risk Endometrial Carcinoma. Society of Gynecologic Oncology, Gynecol Oncol 145(1):17-18, 2017. e-Pub 2017.
75. Westin SN, Taylor J, Sharafi SE, Jazaeri AA, Frumovitz MM, Soliman PT, Sood AK, Lu KH, Mills GB, Vergara-Silva A, Coleman RL. N-DUR: Matched Pair Pharmacodynamics Study of Neoadjuvant Durvalumab in Combination with Chemotherapy in Frontline Ovarian Cancer. ESMO 2017, Annals of Oncology 28(5):122-141, 2017. e-Pub 2017.
76. Westin SN, Litton J, Williams R, Soliman PT, Schmeler KM, Jazaeri AA, Lu KH, Rugman P, Mills GB, Coleman RL. Phase I expansion of olaparib (PARP inhibitor) and AZD5363 (AKT inhibitor) in recurrent ovarian, endometrial and triple negative breast cancer. ESMO 2017 Congress, Annals of Oncology 28(5):122-141, 2017. e-Pub 2017.
77. Dood RL, Fleming ND, Coleman RL, Westin SN, Sood AK. When Advanced Ovarian Cancer is not Ovarian Cancer: Characteristics and Predictors of Non-Ovarian Cancer Pathology in a Systematic, Laparoscopic-Based System. 2017 WAGO Annual Meeting, 2017. e-Pub 2017.
78. Previs RA, Bailey CD, Zaid TM, Huang M, Brown A, Balakrishnan N, Mhadgut H, Pal N, Wei C, Broaddus RR, Bodurka DC, Nick AM, Lu KH, Westin SN. Pathologic Distribution of Disease During Interval Debulking Versus Primary Tumor Reduction in Primary Peritoneal, Ovarian, or Fallopian Tube Carcinoma. 20th Biennial Meeting of the European Society of Gynaecological Oncology (ESGO 2017), 2017. e-Pub 2017.
79. Fleming ND, Westin SN, Coleman RL, Soliman PT, Fellman B, Schmeler KM, Ramirez PT, Lu KH, Sood AK. Complete gross resection at primary versus interval surgery for advanced ovarian cancer improves progression-free survival: a prospective, single-institution study. European Society of Gynecologic Oncology. International J Gyn Cancer 27(4), 2017. e-Pub 2017.
80. Klopp AH, Westin SN. A phase III randomized trial comparing patient reported toxicity and quality of life (QOL) during pelvic IMRT as compared to conventional Ratiotherapy. American Society for Radiation Oncology (ASTRO) Annual Meeting, 2016. e-Pub 2016.
81. Westin SN, Galbraith SM, Godin R, O, Connor MJ, Munsell MF, SAvelieva K, Nick AM, Soliman PT, Sood AK, Mills GB, Coleman RL. WEE WIN: Window of opportunity study of induction Wee1 inhibition in advanced high-grade serous ovarian cancer. J Clin Oncol 34, 2016. e-Pub 2016.
82. Westin SN, Sun CC, Broaddus RR, Pal N, Woodall, Urbauer DL, Ramondetta L, Lu KH, Coleman RL, Bodurka DC. Challenging the Paradigm of Progesterone-Only Therapy for Early Endometrial Cancer: Results of a Prospective Trial of the Levonorgestrel Intrauterine System. 47th Annual Meeting of the Society of Gynecologic Oncologists (SGO), 2016. e-Pub 2016.
83. Westin SN, Sill MW, Coleman RL, Waggoner S, Moore K, Mathews C, Jain A, Modesitt, Schilder R, Aghajanian C. Limited Access Safety Lead-In of the MEK Inhibitor Trametinib in Combination with GSK2141795, an AKT Inhibitor, in Patients with Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study. 47th Annual Meeting of the Society of Gynecologic Oncologists (SGO), 2016. e-Pub 2016.

Book Chapters

1. Zand, B, Westin, SN, Coleman, R. Targeted Therapy in Gynecological Malignancy, 663-680, 2024.
2. Westin, SN, Sood, AK, Coleman, R. Targeted therapy and molecular genetics, 464-488, 2023.
3. Pham, MM, Avila, M, Hinchcliff, EM, Westin, SN. Clinical Application of Poly(ADP-Ribose) Polymerase (PARP) Inhibitors in Ovarian Cancer, 71-89, 2023.
4. Kurnit, KC, Westin, SN, Salani, R. Epithelial ovarian cancer, 250-281, 2023.
5. Frumovitz, M, Westin, SN, Gershenson, DM. Uncommon Gynecologic Cancers, 549-563, 2023.
6. Makker V, MacKay H, Ray-Coquard I, Levine DA, Westin SN, Aoki D, Oaknin A. Endometrial Cancer. In: Nat Rev Dis Primers. 10. John Wiley & Sons Inc, 88, 2021.
7. Previs RA, Mills GB, Westin SN. Novel Therapeutic Approaches an Targets in Ovarian Cancer. In: The Ovary. 3. Academic Press, 2019.
8. Coleman, RL, Lui J, Matsuo K, Thaker PH, Westin SN Sood AK. Section H Gynecological. In: Abeloff's Clinical Oncology Sixth Edition, 1525, 2019.
9. Westin SN, Sood AK, Coleman RL. Targeted Therapy and Molecular Genetics. In: Clinical Gynecologic Oncology. 9. Elsevier/Saunders, 539-560, 2017.
10. Westin SN, Meyer LA, Coleman RL. Ovarian Cancer. In: Targeted Therapy in Translational Cancer Research. Wiley, 2015.
11. Bowser JL, Broaddus RR, Coleman RL, Westin SN. Endometrial Cancer. In: Targeted Therapy in Translational Cancer Research. Wiley, 2015.
12. Bodurka DC, Westin SN, Sun CC. Gynecologic Cancer Survivorship Management. In: Advances in Cancer Survivorship Management. MD Anderson Cancer Care Series. Springer, 125-144, 2014.
13. Westin SN, Broaddus RR. Molecular Targeted Therapies in Endometrial Cancer. In: Endometrial Cancer: A Comprehensive Clinical and Translational Update. Nova Science Pub Incorporated, 2014.
14. Djordjevic B, Westin SN, Broaddus RR. Application of Immunohistochemistry and Molecular Diagnostics to Clinically Relevant Problems in Endometrial Cancer. In: Molecular Oncology. Elsevier, 859-878, 2012.
15. Westin SN, Sood AK, Coleman RL. Targeted Therapy and Molecular Genetics. In: Clinical Gynecologic Oncology. 8th. Elsevier/Saunders, 539-560, 2012.
16. Coleman RL, Westin SN, Ramirez PT, Salvo G, Gershenson DM. Malignant Diseases of the Ovary, Fallopian Tube, and Peritoneum. In: Comprehensive Gynecology. 8. Elsevier Health Sciences.
17. Onstad MA, Lu KH, Westin SN. Tumors of the Uterine Corpus. In: MD Anderson Manual of Medical Oncology. 4. McGraw-Hill Education.

Letters to the Editor

1. Almanza-Huante E, Bataller A, Urrutia S, Gener-Ricos G, Briski RE, Kanagal-Shamanna R, Lu KH, Westin SN, Yap TA, Takahashi K, Ravandi F, Alvarado Y, Kadia T, Sasaki K, Kantarjian HM, Garcia-Manero G. Outcomes of patients with therapy-related myeloid neoplasms after treatment with poly(ADP-ribose) polymerase proteins inhibitors for solid tumours. Br J Haematol 201: e25-e29, 2023.
2. Westin SN, Ramondetta L. Surgical removal of a gigantic abdominal mass: A multidisciplinary approach. Obstet Gynecol 118: 710-1, 2011.